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Cancer is one of the most life-threatening diseases worldwide. Many anticancer treatments 
fail because they are not efficient or reveal too high side effects. Cancer cells develop due to 
unbalances in cell proliferation, cell cycle regulation and/or cell death. Identification of these 
aberrant molecular processes will reveal the essential processes leading to tumor formation 
and allows the generation of potential novel anticancer therapies. Interestingly, a group of 
viral and cellular proteins has been identified that harbors tumor-selective apoptosis activity. 
They are named Proteins Killing Tumor Cells (PKTCs). 
 
The aim of this thesis is to search for cellular processes sensed by the original PKTC, 
apoptin, which distinguish tumor cells from normal cells. Various tumor-related processes 
that are of importance for the tumor-selective activation of apoptin are reported. They range 
from proteasome activity and mitotic regulation to protein kinase and phosphatase action. 
Chapter 2 introduces our current knowledge on the hallmarks of cancer as well as an 
overview of the growing family of PKTCs. We argue that PKTCs might recognize the 
transformed state of a tumor cell via detection of one or more hallmarks of cancer. This 
biological capability of the various PKTCs might be at the base of the switch from cell 
growth to cell death.  
 
Chapter 3 describes two independent lines of research revealing that deregulation of the 
normal function of protein phosphatase 2A (PP2A) is a sufficient step in activating apoptin-
induced cell death. Derailed PP2A activity is increasingly linked to oncogenic transformation 
and especially its involvement during mitosis might be relevant for activation of apoptin. 
Chapter 4 shows that in cancer cells apoptin is insensitive to proteasomal degradation, a 
process that still takes place in normal cells. This cancer-related loss of proteasomal 
susceptibility appears to be specific for apoptin as it is not found for the tumor suppressor 
protein p53. In Chapter 5 the biochemical characterization of the tumor-selective apoptin 
kinase activity implies the existence in tumor cells of a constitutive endogenous kinase that is 
present in both the nuclear and cytoplasmic compartments. Weak inaccuracies in mitotic 
checkpoints are linked to aneuploidy and genetic instability, which are essential for cancer 
development. In Chapter 6 it is shown that apoptin likely senses these inaccuracies during 





All data obtained in this study are discussed in Chapter 7. The systematic analysis of both 
apoptin and other PKTCs reflects various differences between normal and tumor cells. 
Linking-up the various hallmarks of cancer with the aberrant processes sensed by apoptin 
and other PKTCs in cancer cells will hopefully contribute to a better understanding of tumor 







































The past century life expectancy has steadily been increasing with no limit yet in sight 
(Oeppen & Vaupel, 2002; Lee, 2011). Cancer risk increases with age due to the nature of 
tumorigenesis (Anisimov, 2009; Fulop et al., 2011). This implies that a person that gets 
sufficiently old will get cancer. In spite of the fact that cancer has been threatening human 
life since ancient antiquity the perfect cure still has not been found. Current therapies lack 
specificity, killing healthy cells in the process of curing cancer (Pavet et al., 2011). As not to 
spoil the joys of increased life expectancy with the prospect of suffering from a devastating 
disease, drugs with high selectivity are duly needed. 
 
Proteins Killing Tumor Cells (PKTCs) 
In the past two decades proteins emerged from various origins displaying selective anti-
cancer activity. The genes encoding these proteins were dubbed anticancer genes (Grimm & 
Noteborn, 2010) and the corresponding proteins are referred to as PKTCs: Proteins Killing 
Tumor Cells (Bruno et al., 2009). In 1997, apoptin opened the field by showing selective 
apoptosis induction in transformed and malignant cells, while leaving normal cells unharmed 
(Danen-van Oorschot et al., 1997). Several other proteins with similar characteristics soon 
followed. 
Apoptin, E4orf4 and NS1 are produced by viruses; onconase together with Brevinin-
2R are derived from frogs and HAMLET is a milk protein forming a complex with oleic acid 
Interestingly, the largest subgroup of PKTCs are of human origin (TRAIL, mda-7, Par-4, 
Noxa and ORCTL3) showing that cancer can be selectively battled with our own weapons. 
As cancer cells are derived from our own healthy tissue, it was considered for a long 
time impossible to target cancer in a way that would not harm healthy cells. Meanwhile each 
cancer is unique and this diversity made the production of one specific drug seemingly 
unfeasible. In 2000, the publication on the hallmarks of cancer firmly established tumor cells 
as distinct from normal cells with a set of common characteristics allowing the selective 
targeting of malignant tissue (Hanahan & Weinberg, 2000).  
PKTCs can recognize the transformed state of a cancer cell, presumably through the 
recognition of one or more of the hallmarks, and bend the proliferative fate of the tumor 






The Hallmarks of Cancer 
Each cancer is unique in its molecular make-up, however, each cancer cell answers to a 
specific set of capabilities that enabled it to undergo tumorigenesis. These capabilities are 
named ‘the hallmarks of cancer’. They confer upon a cell its tumorigenic potential, while at 
the same time setting them apart from normal cells to such an extent that they can be 
specifically targeted (Hanahan & Weinberg, 2000; 2011).  
 The first hallmark is the ability of cancer cells to sustain proliferative signaling. To 
maintain tissue homeostasis a delicate balance between proliferation, cell senescence and cell 
death is regulated by various types of signaling. For cancer cells to flourish they have to 
maintain growth-promoting signals. They can do this through the manufacturing of growth 
factors themselves or by stimulating neighboring cells to secrete them. Signals are received 
by growth factor receptors. Upregulation or mutation of these receptors also helps to sustain 
the proliferative signal (Lemmon & Schlessinger, 2010). Furthermore by constitutively 
activating the signaling pathways downstream of the growth factor receptors tumor cells can 
create the required environment for continuous growth (Shaw & Cantley, 2006). 
 Apart from upholding a continuous growth signal, a cancer cell has to evade growth 
suppressors, which constitutes the second hallmark. Suppressing signals are sent both from 
outside a cell as well as from the inside. Growth suppression is regulated by surrounding 
cells to prevent uncontrolled cell proliferation and to avert damaged cells from passing on 
potential dangerous alterations to progeny. Cancer cells circumvent this block on their 
generation by the downregulation of tumor suppressor genes such as RB and TP53 
(Burkhart & Sage, 2008; Levine et al., 1991).  
 When tissue homeostasis is threatened by aberrant growth, triggers for programmed 
cell death are emitted. Activation of tumor suppressors due to cellular defects leads to cell 
death pathways preventing the formation of malignant cells. For tumorigenesis to proceed, 
the third hallmark has to be obeyed, resisting cell death. This can be achieved by altering the 
balance between pro-survival and pro-death proteins (Hanahan & Weinberg, 2011; Adams & 









Box 2.1 Various types of cell death 
One of the hallmarks of cancer cells is the resistance against cell death signaling. 
Programmed cell death is important during (embryonic) development and to maintain tissue 
homeostasis. Several types of cell death have been recognized and all are highly regulated in 
order to prevent tissue inflammation, excessive cell death and transformation. In 2011 the 
Nomenclature Committee on Cell Death proposed to no longer identify cell death types by 
their morphological features, but rather relate them to a subset of biochemical features 
(Galluzzi et al., 2012).                                                                               
Apoptosis (a) is the most common and well-described programmed cell death. 
Rounding-up of the cell, reduction of cellular volume, chromatin condensation, nuclear 
fragmentation, membrane blebbing and engulfment by phagocytes are the morphological 
features of apoptosis (Kroemer et al., 2009). It has two distinct routes, intrinsic and extrinsic. 
Both are dependent on the caspase cascade, the proteases responsible for most of the 
apoptotic morphology. The extrinsic pathway is triggered by binding of extracellular stress 
signals to receptors, whereas the intrinsic pathway is regulated by intracellular conditions 
(Galluzzi et al., 2012). The clearance of the apoptotic cell remnants by phagocytes means 
that there is no immune response. 
    
apoptosis: caspase activatioin 
  pyknosis 
  nuclear condensation and DNA fragmentation 
  phosphatidylserine exposure 
  ROS generation 
  loss of mitochondrial membrane potential 
 
necrosis: ROS generation 
  loss of mitochondrial membrane potential 
  plasma membrane rupture 




  LC3 lipidation 
 
Apoptosis (a), necrosis (b) and autophagy (c) main cell death characteristics, adapted from Kepp et al. 
(2011). 
 
Necrosis (b) is characterized by swelling of both the cell and its organelles, rupture of 
the plasma membrane and the loss of intracellular contents (Kroemer et al., 2009). For a 
long time it was considered to be unregulated and as such the opposite of apoptosis. 
However, regulated necrosis has been shown to happen after various cellular triggers, no 





regulation of death receptors can opt for necrosis in the absence of a functional caspase 
route (Declercq et al., 2009). As such necrosis is a backup mechanism when apoptosis is not 
an option. Furthermore the release of intracellular molecules triggers an innate immune 
response which in some situations, e.g. viral infection, is more desirable than the neat clean 
up after apoptosis. 
Autophagy (c) is primarily a survival process during starvation. During low nutrient 
conditions cytoplasmic material is collected in a double membrane vesicle, the 
autophagosome, which fuses with lysosomes, leading to the degradation of the contents 
(Denton et al., 2012). Autophagic cell death was coined for a type of cell death that is 
accompanied by massive cytoplasmic vacuolization and the upregulation of the autophagy 
markers such as LC3 puncta (Galluzzi et al., 2012). However, it is not surprising that in the 
situation preceding cell death, autophagy is upregulated as a survival strategy (Denton et al., 
2012). 
Mitotic catastrophe (d) was originally defined as ‘death during mitosis’. During the 
elucidation of the molecular processes defining mitotic catastrophe it was concluded that it is 
not a ‘pure’ cell death mechanism, but rather an oncosuppressive mechanism that results in 
apoptosis or senescence (Galluzzi et al., 2012). It is characterized by perturbations of the 
mitotic machinery, starts during M phase, is paralleled by some degree of mitotic arrest and 




Mitotic catastrophe caused by perturbations of the mitotic machinery. 
 
In the past years more cellular types of programmed cell death were biochemically 
characterized, i.e. anoikis, necroptosis, cornification, entosis, netosis, parthanatos and 
pyroptosis. Often they are restricted to specific cell types and linked to a very distinct trigger. 
 
 In order to become a multi-cellular tumor cancer cells have to overcome the 
regulatory mechanisms of the environment that could stop their growth, as the previous 
three hallmarks indicate. There are also internal controls to prevent neoplasia. Cells have a 
natural build-in replication limit regulated by the telomere length, the ends of the 
chromosomes that naturally shorten during each cell division. When telomeres have 
shortened sufficiently after the maximum number of divisions cells go into senescence, a 
non-proliferative but viable state (Hayflick, 1997). This internal block has to be overcome by 
cancer cells, enabling replicative immortality. The most common way that this happens is by re-
activation of telomerase, an enzyme that can lengthen telomeres. Alternative lengthening of 




telomeres is a second option and depends on homologous recombination of the telomere 
repetitive DNA (Cesare & Reddel, 2010). 
 As any tissue a multi-cellular tumor is in need of sustenance. After reaching a 
minimal size the regular vasculature of the human body is no longer sufficient to provide the 
nutrients needed by the budding tumor. In order to feed all the tumor cells new vessels will 
have to be created in a process referred to as inducing angiogenesis. In healthy adults 
angiogenesis is a rare process that is only transiently switched on in situations as for instance 
wound healing. During tumorigenesis it has to be turned on permanently, a process referred 
to as the ‘angiogenic switch’ (Weis & Cheresh, 2011).  
 The next hallmark in tumor development is activating invasion and metastasis. 
Reprogramming of the cell through the epithelial-mesenchymal transition (EMT) allows cells 
to detach from the surrounding cells and extracellular matrix without inducing cell death. 
With these newfound capabilities the cancer cell is no longer dependent on its original 
surrounding tissue for survival, a new settlement can be set up in a different part of the body 
(Valastyan & Weinberg, 2011).   
In 2011, the list of hallmarks was extended with two more biological capabilities 
acquired by cancer cells. Furthermore two characteristics enabling the tumorigenic process 
were defined (Hanahan & Weinberg, 2011). 
 Cells have two main pathways for the generation of energy from glucose, the choice 
depends on the availability of oxygen. Cancer cells reprogram their energy metabolism to a 
state termed ‘aerobic glycolysis’ also known as Warburg effect, meaning that even when 
enough oxygen is present they do not purely rely on oxidative phosphorylation as normal 
cells would under that circumstance (Koppenol et al., 2011). Deregulation of cellular energetics is 
an emerging hallmark. The switch leaves cancer cells addicted to glycolysis for their ATP 
production and sensitive to perturbations of this pathway (Pelicano et al., 2006).  
 The human body is under constant surveillance of the immune system. The immune 
system is capable of detecting and destroying malignant cells and prevents their outgrowth. 
However, it also creates a tumor environment that supports development of cancer cells that 
can avoid immune destruction. Tumor cells might have lost their characteristic tumor antigen 
expression by e.g. the down regulation of their major histocompatibility complex class I 






 Together, the eight hallmarks described above (summarized in figure 2.1) bestow on 
a normal cell the ability to become a cancer cell. Acquisition of the hallmarks happens due to 
the so-called enabling characteristics, genome instability and tumor-promoting inflammation. The 
immune system can prevent neoplasia, however, inflammation can also contribute to several 
of the hallmark capabilities by supplying bioactive molecules (Grivennikov et al., 2010). 
 The biological characteristics described by the hallmarks can in general be achieved 
through alterations in the genome (Aquilera & Gomez-Gonzalez, 2008). Point mutations, 
aneuploidy and epigenetic alterations can change the activity of oncogenes and tumor 
suppressors, allowing a cell to obtain one hallmark at a time (Negrini et al., 2010).  
 
 
Figure 2.1: The hallmarks of cancer and enabling characteristics adapted from Hanahan & Weinberg, 2011. 
Schematic representation of the hallmarks of cancer as they, together with the enabling characteristics, create 
the tumor microenvironment allowing cancer progression to take its course. 
 
Targeting Tumor-Related Processes 
Chemical anticancer drugs are designed to target one component in a pathway relevant to 
one, or a few, of the hallmarks of cancer. While having the desired effect of crippling the 
cancer by poking at one of its foundations, usually the drug target also has an important 




function in normal cells. Synthetic anticancer drugs might as such be too simplistic to take 
full advantage of the differences between normal, and tumor cells. The PKTCs supplied by 
nature can act selectively on cancer cells; the question is if they do this by recognizing the 
transformed state of a tumor through the detection of the hallmarks, and if it is this 
biological capability that makes that PKTCs can switch cells towards cell death. 
 
PKTCs targeting hallmarks of cancer 
To analyze the relationship between the hallmarks of cancer and PKTCs the main 
characteristics of these proteins, and the cellular characteristics by which they were found to 
distinguish between normal and tumor cells, will be described below.  
 
apoptin 
Apoptin is the Viral Protein 3 (VP3) of Chicken Anemia Virus (CAV). CAV is the causative 
agent of aplastic anemia in young chickens, leading to high death rates due to depletion of 
thymocytes. CAV is particularly lethal in combination with Marek’s disease, an oncogenic 
DNA virus pathogen (Noteborn et al., 1991; Osterrieder et al., 2006). In transformed 
chicken cells CAV causes apoptosis. This effect is attributed to VP3 as expression of this 
protein alone is sufficient to induce apoptosis. As such VP3 was renamed apoptin 
(Noteborn et al., 1994). 
 Apoptin can induce cell death in human tumor cells, but is harmless towards healthy 
human cells, making it the first Protein Killing Tumor Cells (Zhuang et al., 1995; Danen-van 
Oorschot et al., 1997). Apoptin was shown to induce apoptosis in over 70 cancer cell lines in 
a p53-independent fashion (Backendorf et al., 2008). Apart from the selective apoptosis 
induction apoptin shows more differential behavior between normal and tumor cells. In 
cancer cells apoptin translocates to the nucleus whereas in normal cells it stays in the 
cytoplasm. The nuclear localization is regulated by a bipartite nuclear localisation sequence 
(NLS) and the nuclear transport is correlated to the apoptosis induction. However, forced 
nuclear localization of apoptin in normal cells is not sufficient to trigger cell death (Danen-
van Oorschot et al., 2003). Apoptin has a CRM1-recognized nuclear export signal (NES) 
that allows the apoptin protein to return to the cytoplasm in normal cells (Poon et al., 2005). 





apoptin, namely the cancer-specific phosphorylation of threonine 108 (Rohn et al., 2002; 
Poon et al., 2005) (box 2.2).  
Box 2.2 Phophatases and kinases; the cellular on/off switchers 
Protein activity can be regulated by phosphorylation, the attachment of a phosphate group 
from a high energy donor as e.g. ATP to a Ser/Thr or Tyr of the protein. Phosphorylation 
can switch on or off the activity of a protein based on the modified amino acid and the 
related (structural) changes (Johnson & Lewis, 2001). Protein kinases are the enzymes 
responsible for phosphorylating events. Over 500 putative kinases have been identified in 
the human genome. Due to their crucial role in regulating cellular pathways many kinases are 
related to disease (Manning et al., 2002). The cellular targets of kinases are often other 
kinases, leading to phosphorylation cascades. Constitutive activation of a kinase through 
mutation is a common trigger for several of the hallmarks of cancer, as for example 
oncogenic casein kinase II and sustainment of proliferative signaling (Hanf et al., 2010). 
Their central role in (oncogenic) signaling makes kinases a popular target in anti-cancer drug 
design (Gherardi et al., 2012; Canavese et al., 2012). 
Phosphorylation is a reversible process that can be counteracted by phosphatases. 
Whereas there is a wealth of kinases available, only a small number of phosphatases is at the 
cell’s disposal (estimated at 30 for ser/thr phosphatases and 107 for tyr phosphatases). 
Instead of shear numbers, phosphatase specificity is regulated by a large number of 
exchangeable regulatory subunits (Shi, 2009). For example the protein phosphatases 2A 
(PP2A) consists of three subunits, a scaffold (Aα or Aβ), a catalytic part (Cα or Cβ) and a 
regulatory subunit determining localization and specificity (B55, B56, PR72 and PR93 
families). Over 60 different PP2A compositions are known to be possible (Mumby, 2007). 
Where kinases are often oncogenes, phosphatases are more likely involved in cancer 
formation as tumor suppressors. PP2A subunits are targeted by oncogenic viruses and over-
expression of PP2A inhibitors support the establishment of several hallmarks of cancer 
(Westermarck & Hahn, 2008). 
 
 
Phosphorylation of a protein can either switch the activity on or off. This is a reversible event controlled by 
the balanced actions of kinases and phosphatases.  
 
 In the field a consensus on the kinase responsible for this modification has not yet 
been reached (for details see chapter five). Maddika et al. (2009) reported that aberrant 
activation of cyclin-dependent kinase 2 (CDK2), complexed with cyclin A, leads to apoptin 
phosphorylation in the nucleus. This cell cycle regulated complex becomes specifically 




activated in tumor cells due to the translocation of Akt from the cytoplasm to the nucleus. 
Cellular relocalizations of Akt are caused by apoptin itself which interacts with Akt and 
brings it to the nucleus (Maddika et al., 2007). Phosphoinositide 3-kinase (PI3K) functions 
upstream of Akt. Apoptin activates PI3K through interaction with one of its subunits 
(Maddika et al., 2008). The PI3K/Akt pathway is often over-activated in cancer, promoting 
proliferation and suppressing cell death (Vivanco & Sawyers, 2002). Meanwhile Jiang et al. 
(2010) showed that down-regulation of protein kinase C isoform β (PKCβ) significantly 
reduced apoptin phosphorylation in several cell lines. PKCβ positively influences 
proliferation in cancer cells (Li et al., 2011b). 
 In normal cells apoptin forms in time granules in the cytoplasm, becomes epitope-
shielded and eventually it can no longer be detected (Zhang et al., 2003). The tumor-specific 
behavior of apoptin can be triggered in normal cells by transformation with the SV40 large 
and small T antigen (Zhang et al., 2004). At its N-terminus apoptin has a leucine-rich-region 
which is responsible for many of its protein-protein interactions (Backendorf et al., 2008). 
One of the most important interaction partners of apoptin is apoptin itself. Apoptin forms 
globular multimers that induce apoptosis (Leliveld et al., 2003b).   
 Apoptin binds to DNA directly (Leliveld et al., 2003a). Furthermore it interacts with 
DEDAF (death effector domain associated factor) (Danen-van Oorschot et al., 2004). 
DEDAF is a transcriptional repressor that changes conformation upon binding to DNA 
(Neira et al., 2009). DNA damage leads to p53 stabilization through DEDAF, which is down 
regulated in tumor cells marking it as tumor suppressor (Chen et al., 2009). Apoptin can be 
activated in normal cells by DNA damage response (DDR) signaling. Knockdown of key 
factors in DDR can block apoptin activity in tumor cells (Kucharski et al., 2011). Either 
directly or indirectly, apoptin seems capable of detecting damaged DNA. 
 Apoptin can block the cell cycle in G2/M (Box 2.3 and 2.4) through interaction with 
a subunit of the anaphase promoting complex/cyclosome (APC/C) (Teodoro et al., 2004). 
APC/C is an E3 ubiquitin ligase charged with the task of maintaining genetic stability (Box 
2.5) (Lipkowitz & Weissman, 2011). Through upregulation of ceramide levels and the 
cytoplasmic translocation of Nur77 apoptin induces apoptosis (Liu et al., 2006; Maddika et 
al., 2005). The apoptosis induction is p53-independent. Instead, apoptin functions through 
p53-family member p73, upregulating the pro-death proteins Puma and Noxa (Box 2.6) 





favor of the pro-death TAp73. This is mediated by stimulating the ubiquitin ligase PIR2 
which targets the anti-apoptotic ΔNp73 isoform for degradation (Taebunpakul et al., 2012). 
Box 2.3 The cell cycle 
An important facet of life is the ability to create progeny. One cell passes on its information 
to its two daughter cells during cell division. When the correct signals are present a cell will 
continue with the circle of life, the cell cycle. There are two main events in the cell cycle, the 
duplication of the DNA in S phase, and the correct distribution of the two sets of 
chromosomes over the two daughter cells during M phase. These two phases are separated 
by two gap phases, G1 and G2 (Alberts et al., 2008). When not enough growth signals are 
present a cell can withdraw from the cell cycle during G1, into some quiescent state named 
G0. Once the stop-or-go moment in G1 has been passed a cell is committed to complete the 
circle. 
 At several points during the cell cycle there are checkpoints to ensure that the cell 
continues to the next step, only when all appropriate measures have been taken. The first 
checkpoint is the stop-or-go moment during G1 that assures that the cell is prepared for the 
duplication of the DNA. Correct copying of the DNA and the repair of DNA damages is 
closely monitored during the S phase and as long as this is not accurately terminated the 
progression of the cell cycle is blocked. When blocks of the cell cycle exceed a certain 
amount of time, survival signaling is switched towards a cell death execution pathway. 
During G2 all the needs for the physical separation of the two cells during M phase are 
prepared (box 2.4 mitosis). The G2/M checkpoint is the last hurdle before the start of 
mitosis. Checkpoints work through the (de)activation of cyclin-dependent kinases (CDKs), 
which are transiently activated by binding of cyclin. Activity is quickly shut down by 
degradation of the activating cyclin, making it a very fine-tuned and fast-reacting system. A 
weakening of the strictness of the checkpoints opens the door for cancer hallmark 
acquisition (Kastan & Bartek, 2004). 
 
 
The cell cycle and its checkpoints (adapted from Kastan & Bartek., 2004)  
 




Box 2.4 Mitosis 
Mitosis (M phase) is the actual division of one cell into two daughter cells. The faithful 
distribution of the duplicated DNA is tightly regulated to prevent aneuploidy and genetic 
instability (Kops et al., 2005). Mitosis can be split into several stages. At the start of M phase, 
prophase (a), the chromosomes condense. In the cytoplasm the centrosome (the 
microtubule organizing centre) is duplicated, allowing the formation of two spindles. During 
prometaphase (b) the nuclear membrane disintegrates and the spindle microtubules can 
attach to the kinetochores of the chromatids (Alberts et al., 2008). Correct attachment is 
closely monitored, unattached kinetochores signal to activate the spindle attachment 
checkpoint (SAC), blocking mitotic progression (Elowe, 2011). During metaphase (c) the 
chromosomes align and the SAC requirements are met by the attachment of the entire sister 
chromosomes to the correct spindle. This leads to the meta-to-anaphase transition. The 
APC/C (anaphase promoting complex/cyclosome) orchestrates this switch that allows the 
separation of chromosomes towards separate daughter cells during anaphase (d). Telophase 
(e) marks the moment the two sets of DNA are fully segregated and packaged again within a 
nuclear envelope. Finally cytokinesis splits the cell in two (f) (Alberts et al., 2008). 
 
 
The six phases of mitosis adapted from Scholey et al. (2003). a) prophase, b) prometaphase, c) metaphase, d) 











Box 2.5 The ubiquitin-proteasome degradation system 
Cellular events are tightly regulated on many levels as e.g. transcription initiation, protein 
activation and protein degradation. The selective degradation of many proteins is tightly 
orchestrated by the ubiquitin-proteasome system. When a protein has served its purpose it is 
tagged for disposal by the covalent attachment of ubiquitin, a 76 amino acid protein. This 
tagging is performed by three enzymes. E1 binds and activates ubiquitin. E2 is a ubiquitin-
carrier protein that temporarily holds on to the activated ubiquitin. Finally the E3 ubiquitin 
ligase transfers the ubiquitin to the lysine residue of the target protein. There are many E3 
families and E3 multisubunit complexes which determine ubiquitination specificity in time 
and space (Hershko & Ciechanover, 1998). 
 Ubiquitinated proteins are recognized and degraded by the 26S proteasome. The 
proteasome is a multiprotein, ATP-dependent protease. It consists of the 20S active core and 
two 19S regulatory caps. These are themselves composed of several subunits. The caps bind 
ubiquitinated proteins and ‘feed’ them to the core. The core is made up of α- and β-rings. 
From these rings the β1, β2 and β5 subunits have protease activity and can cleave peptides 
bonds after various amino acids (Murata et al., 2009). 
 Most cells use the same regular proteasome subunit composition. Hematopoetic cells 
constitutively express the immunoproteasome. There the β1, β2 and β5 subunits are replaced 
by β1i β2iand β5i resulting in different substrate specificity and alternative peptides (Huber 
et al., 2012). The β5t subunit is exclusively expressed in the thymus aiding positive T cell 
selection (Murata et al., 2007). 
 Altered protein stability can promote cancer formation and disease development in 
general. Many of the proteins involved in ubiquitination can be mutated in cancer, 
supporting roles as oncogenes or tumor suppressor. For example the anaphase promoting 
complex/cyclosome (APC/C) is an important E3 ligase regulating the progression through 
mitosis. Changes in this process support aberrant growth (Lipkowitz & Weissman, 2011). 
Targeting the ubiquitin-proteasome system is a popular approach in cancer therapy. Shifting 
the balance between pro-survival and pro-death proteins by changing their stability can 
trigger cell death induction in a semi-cancer-specific way (Hoeller & Dikic, 2009). 
 
 
26S proteasome subunit composition, adapted from Murata et al. (2009). 




Box 2.6 The Bcl-2 family 
The Bcl-2 family of proteins governs the switch between life and death. In the cell death 
pathways described in box 2.1 there is a moment in the cascade of events that can be 
considered as a ‘point-of-no-return’. Cellular changes in the beginning of cell death are 
reversible, at some point a modification is made, or a complex formed, that is irreversible. 
From then on a cell is committed to die. The decision of commitment is made by the Bcl-2 
family in the situation of intrinsic apoptosis. Internal stress signals such as DNA damage and 
low nutrients are sensed by the Bcl-2 family inducing a loss of mitochondrial membrane 
potential. This leads to leakage of cytochrome C, activation of the apoptosome and 
subsequent caspase activation (Tait & Green, 2010).  
The Bcl-2 family can be roughly split in three groups. The name-giver, Bcl-2 (B-cell 
lymphoma 2), is a pro-survival protein. Together with Bcl-xL, Bcl-w, Mcl-1 and A1, Bcl-2 
inhibits cell death by associating with the mitochondrial outer membrane, preventing the 
release of cytochrome and related pro-apoptosis factors. Furthermore they inhibit (indirectly) 
the pro-death proteins Bax and Bak (Cory & Adams, 2002).  
BH3-only clan members only share one domain with the others, the Bcl-2 homology 
(BH) 3 domain. They are pro-apoptotic and function upstream of the Bcl-2 like proteins. 
There are at least eight family members, including Noxa and Puma. The BH3-only proteins 
interpret intercellular signals and when activated they bind and inactivate the pro-survival 
Bcl-2 family members. Not all BH3-only proteins bind all Bcl-2-like relatives, creating an 
extra level of mechanistic control. Furthermore, some are controlled by modifications, while 
others are bound by inhibitors (Cory & Adams, 2002). For example, Puma and Noxa are 
controlled by the p53 family of DNA damage sensors on a transcriptional level. Puma can 
inactivate all pro-survival members whereas Noxa only controls Mcl-1 and A1 (Adams & 
Cory, 2007).  
The actual piercing of the mitochondria membrane is done by the third group, 
composed of the proteins Bax and Bak. Upon activation they undergo a conformational 
change and oligomerize to form pores in the mitochondrial membrane, allowing pro-death 
factors to leak out (Westphal et al., 2011). Bax and Bak can be directly activated by BH3-only 
proteins, or by the removal of the block of Bcl-2 like relatives by the same BH3-only 
members (a) (Adams & Cory, 2007). In the end it is the balance between active pro-survival 
and pro-death proteins that determines the outcome, survival or apoptosis (b/c). 
 
 
The balance between Bcl-2 family members constitutes the switch between life and death. a) BH3-only 
proteins can directly and indirectly activate Bax and Bak, leading to loss of mitochondrial membrane loss 
and caspase activation. b/c) It is the balance between the different family members that determines the 






For many years CAV was the only member of the genus Gyrovirus. The sequencing of 
a DNA virus causing apathy and weight-loss in Brazillian chicks led to the discovery of a 
sequence 40% identical with the CAV genome. The new family member is named Avian 
gyrovirus 2 (AGV2). AGV2 shows a similar genomic organization as CAV, with an orf2 
resembling VP3 (apoptin) of CAV. The leucine-rich-region, NES and bipartite NLS are 
conserved in the AGV2 version of apoptin (Rijsewijk et al., 2011). A third gyrovirus (GyV3) 
was detected in human faeces from Chilean children, presumably reflecting chicken 
consumption (Phan et al., 2012). Apart from the identification of new gyroviruses, the 
sequencing of CAV derived from several different areas allowed subtyping of the CAV 
genotypes (Eltahir et al., 2011) 
 In 2011 a human gyrovirus (HGyV) was isolated from a skin swab. This virus shows 
similar gene organization as CAV and encodes a homologue of apoptin (Sauvage et al., 2011). 
HGyV could only be detected in the blood of immune-compromised patients and not of 
healthy individuals (Maggi et al., 2012). The HGyV apoptin has the same subcellular 
distribution as CAV-derived apoptin and shows tumor-selective apoptosis induction, 
resembling the original apoptin (Bullenkamp et al., 2012).  
 The four VP3 proteins show different levels of sequence similarity. All the 
confirmed important domains of apoptin however are conserved (Figure 2.2): i.e. the 
isoleucine-rich region, the bipartite nuclear localization signal, the nuclear export signal and a 
relevant threonine residue in between the latter are all present in the same order in all four 
VP3 proteins. As the human gyroviral VP3 has clear tumor-selective apoptosis inducing 
activity, it is very likely the other two also resemble apoptin in this aspect. 
 
Figure 2.2: Sequence alignment of viral protein 3 of the 4 known gyrovirusses (ClustalW  
http://www.ebi.ac.uk/Tools/msa/clustalw2/). In color indicated regions are confirmed for apoptin and 
putative for the other VP3s (references in text). Blue: isoleucine-rich region, Yellow: Nuclear Localisation 
Sequence, Green: Nuclear Exit Sequence, Red: relevant threonine residue. 





E4orf4 is a 14kDa protein encoded by the E4 early transcription unit of adenovirus. Tumor-
selective cell death is induced by E4orf4 through mitotic catastrophe resulting in necrosis (Li 
et al., 2009a). Prior to cell death a G2/M block is triggered which is linked to the interaction 
of E4orf4 with the APC/C (Kornitzer et al., 2001). As for apoptin, the APC/C links E4orf4 
to genome instability which is caused by inaccuracies during mitosis (Weaver & Cleveland, 
2005; Lipkowitz & Weissman, 2011).  
 To acquire cell death inducing activity E4orf4 needs to be phosphorylated by Src 
kinases (Gingras et al., 2002). Furthermore, E4orf4 disrupts Src signaling in tumor cells 
promoting cell death induction (Lavoie et al., 2000). The Src family kinases link E4orf4 to 
several main cancer characteristics such as angiogenesis and invasion (Arai et al., 2012). 
 E4orf4 interacts with the B55 subunit of the tumor-suppressor protein phosphatase 
2A (PP2A). Interaction attenuates PP2A activity, lowering overall dephosphorylation and 
changing substrates (Li et al., 2009b). PP2A is a key player in PI3-kinase signaling and 
through that pathway involved in many hallmarks of cancer (proliferative signaling, evading 
growth suppressors, resisting cell death) (Westermarck & Hahn, 2008).  
E4orf4 directs PP2A to the chromatin-remodeling complex of ACF (ATP-
dependent chromatin-remodeling factor) with the chromatin-remodeling factor SNF2h 
(sucrose non fermenting-2h). SNF2h can form chromatin-remodeling complexes with other 
co-enzymes as for example RSF1 (remodeling and spacing factor 1) and WSTF (Williams-
Beurens syndrome transcription factor), all having different chromatin remodeling 
specificities. The PP2A-E4orf4 complex is thought to remove ACF from its complex, 
liberating SNF2h to form complexes with other cofactors. This switch in chromatin 




The third viral PKTC is derived from oncolytic parvoviruses. The autonomous parvovirus 
MVM (minute virus of mice) and H-1 (natural host is rat) were shown to preferentially lyse 
transformed cells (Rommelaere & Cornelis, 1991). This cancer-selectivity is attributed to 
more efficient viral replication in tumor cells (Rommelaere et al., 2010). Furthermore it is 





 NS1 can induce tumor-specific cell death independent of p53 through various 
pathways including apoptosis (Mincberg et al., 2011), autophagy (Di Piazza et al., 2007) and 
mitotic catastrophe (Fragkos & Beard, 2011). The human parvovirus B19 NS1 protein can 
trigger apoptotic cell death in HepG2 cells through DNA damage infliction and a 
consequent S phase arrest (Kivovich et al., 2012). 
 The main effector of NS1 is casein kinase II (CKII). Inhibition of CKII protects 
cells from NS1-induced cell death. NS1 interacts with CKII and modulates its selectivity, e.g. 
NS1-CKII leads to altered tropomyosin phosphorylation. CKII-dependent cytoskeletal 
rearrangements and cell death induction are modified by NS1 as well (Nuesch & 
Rommelaere, 2007). CKII has a significant influence on cell growth and proliferation 
through its substrates. Upregulated CKII activity is related to cancer development through 
both the aberrant activation of oncogenes and downregulation of tumor suppressor activity 
by phosphorylation (Hanif et al., 2010). In addition over-expression of CKII also suppresses 
apoptosis induction via the extrinsic pathway (Wang et al., 2005). 
 The oncoselectivity of the whole parvovirus is closely interwoven with the altered 
immunogenic state of cancer cells. In normal cells parvoviral particles are detected resulting 
in an interferon response. In contrast, in tumor cells there is a block on the activation of this 
pathway (Rommelaere et al., 2010). Parvovirus immune modulation goes further; after cell 
death induction an anti-tumor immune-response is triggered by the release of tumor-
associated antigens (Moehler et al., 2005; Grekova et al., 2011). 
 
Onconase 
Onconase (ranpirnase) is a ribonuclease isolated from the oocytes of the Northern leopard 
frog (Rana pipiens). It has preferential cytotoxic activity in tumor cells as compared to normal 
cells, likely due to selective internalization by tumor cells (Lee & Raines, 2008). Onconase is 
a highly cationic protein (pI>9.5) improving the interaction with the more negatively charged 
tumor cell membrane (James et al., 1956; Riedl et al., 2011). Treatment with the protein 
reduces cell proliferation and invasion (Goparaju et al., 2011). 
 Onconase preferentially degrades tRNAs and miRNAs. Destruction of tRNAs 
blocks protein synthesis, eventually inducing apoptosis (Iordanov et al., 2000). By cleavage of 
miRNA precursors onconase reduces the amount of mature miRNAs (Qiao et al., 2012). 
One of the downstream miRNA targets influenced by onconase is NF-κB (nuclear factor 




kappa B) (Goparaju et al., 2011). NF-κB is deregulated in many types of cancer stimulating 
proliferation (Rayet & Gelinas, 1999); loss of this oncogene likely supports onconase-
induced cell death.  
 
Brevinin-2R 
Brevinin-2R is a defensin derived from the skin of another frog species, Rana ridibunda. This 
25-amino acid peptide shows higher cell death induction in several cancer cell lines 
compared to normal cell lines. Caspase activation is dispensable for the activity that seems to 
function through the autophagic cell death pathway. Selectivity is attributed to the increased 
binding of Brevinin-2R to the membrane of cancer cells in a fashion reminiscent of 
onconase (Ghavami et al., 2008). Tumor cells have a different cellular membrane 
composition. Especially, phosphatidylserine, sialic acid or heparan sulfate, representing 
negatively charged membrane components, are differently organised between cancer and 
normal cells (Riedl et al., 2011). Membrane composition changes further to allow invasion 
and metastasis (Kier, 1990), a trait that is likely recognized by onconase and Brevinin-2R. 
 
HAMLET 
Human alpha-lactalbumin made lethal to tumor (HAMLET) is a protein derived from 
human milk which is partially unfolded in vitro and forms a complex with oleic acid.  Its 
tumoricidal activity was discovered when it induced apoptosis-like death in human tumor 
cells during an experiment to show the effect of milk on bacterial attachment to lung 
carcinoma cells (Hakansson et al., 1995). HAMLET can bind and cross the cellular 
membrane, accumulating in the nucleus of tumor cells. Cellular membrane traffic is less 
efficient in untransformed cells, where the protein complex remains in the cytoplasm 
forming small aggregates (Fischer et al., 2004). Possibly the membrane binding and crossing 
difference between normal and tumor cells of HAMLET can be attributed to similar changes 
as those that facilitate onconase and Brevinin-2R entrance as described above. In the nucleus 
of tumor cells HAMLET binds histones and disrupts the chromatin structure (Duringer et 
al., 2003). 
 Morphologically HAMLET induces an apoptosis-like cell death with cytochrome c 
release, caspase activation, phosphatidylserine exposure and DNA fragmentation. However, 





death (Hallgren et al., 2006). Instead the anti-tumor effect of HAMLET was shown to be 
dependent on components of the autophagy pathway (Aits et al., 2008). 
 The partially unfolded state is relevant to the activity of HAMLET. Unfolded 
proteins are normally degraded by the proteasome (see box 2.5 protein degradation). 
HAMLET is targeted to the 20S proteasome but resists degradation. By binding it inhibits 
proteasome activity and disrupts the structure (Gustafsson et al., 2009). Alteration of the 
degradation of cellular proteins might contribute to the lethal effect of HAMLET. 
The connection of HAMLET to the hallmarks of cancer became clear with the 
knockdown of c-Myc. Lack of this oncogene suppressed the cell death induction by 
HAMLET (Storm et al., 2011). In the same study it was shown that the modified 
metabolism in cancer cells is a crucial factor in the activity of HAMLET. Over-expression of 
the transcription factor c-Myc has an effect on proliferative signaling, energy metabolism, 
angiogenesis, invasion and survival (Hanahan & Weinberg, 2011). 
 
TRAIL 
TRAIL is tumor necrosis factor-related apoptosis-inducing ligand (or Apo2 ligand Apo2L) 
and a member of the tumor necrosis factor (TNF) superfamily of cytokines. TNF family 
members induce apoptosis by binding to their respective transmembrane receptors. TRAIL 
is a transmembrane protein that can become extracellularly cleaved, leaving a soluble 
signaling protein that can form homotrimers (Wang and El-Deiry, 2003). TRAIL binds to 
death receptors 4 and 5 (DR4 and DR5). Binding leads to oligomerization of the receptors 
and activation of the death domain, starting the extrinsic apoptosis pathway (Mahalingam et 
al., 2009). TRAIL specifically induces apoptosis in tumor cells (Walczak et al., 1999). TRAIL 
protects against tumor development and metastasis (LeBlanc & Ashkenazi, 2003). 
 The tumorigenic c-Myc pathway positively influences TRAIL-induced apoptosis 
(Kim et al., 2011). c-Myc upregulates DR5 cell surface levels (Wang et al., 2004) and down 
regulates the inhibitor of caspase activation FLIP (FLICE inhibitory protein) (Ricci et al., 
2004) potentiating the cell death activities of TRAIL. Normal cells can be made sensitive to 
TRAIL by using oncogenic Ras mutants which increase the recruitment of caspase-8 to the 
death receptors. Interestingly, immortalizing cells with SV40 early region and telomerase is 
not enough to trigger TRAIL-mediated cell death (Nesterov et al., 2004). 




Not all cancer cells are equally sensitive to TRAIL (Dimberg et al., 2012). A lot of 
effort is invested in modulating cancer-specific pathways in order to re-sensitize cells to 
TRAIL, through combination treatment with for example cisplatin, proteasome inhibitors, 
NF-κB inhibitors and PI3K inhibitors (Johnstone et al., 2008). In cancer cells resistant to 
TRAIL treatment, TRAIL can actually stimulate tumorigenesis. When the apoptotic signal is 
not strong enough, e.g. by over-expression of anti-apoptotic proteins, TRAIL-triggered 
pathways promote proliferation, survival and metastasis by upregulating NF-κB and 
activating the PI3K-Akt pathway (Johnstone et al., 2008; Chi et al., 2012). 
 
Noxa 
Noxa is a BH3-only protein involved in, but not limited to, the p53-regulated apoptosis-
induction following cellular stress (see box 2.6). Upon cellular stress the expression of pro-
death BH3-only proteins is upregulated, including Noxa and Puma. They bind and thereby 
inactivate the pro-survival proteins, activating the mitochondrial cell death pathway. In 
cancer cells Bcl-2 and related pro-survival proteins are regularly upregulated to confer cell 
death resistance upon the tumor (Adams & Cory, 2007).  
 Over-expression of Noxa was found to selectively induce apoptosis in tumor cells, 
whereas Puma over-expression led to cell death in all types of cells (Suzuki et al., 2009). 
Puma interacts with all pro-survival family members while Noxa only influences a select 
subgroup (Adams & Cory, 2007). Importantly Noxa interacts with anti-apoptotic protein 
myeloid cell leukemia-1 (Mcl-1), targeting it for proteasomal degradation (Ploner et al., 2009). 
Oncogenic c-Myc stimulates tumorigenesis. During the process c-Myc also increases 
expression levels of Noxa, though not to such an extent that the balance in the Bcl-2 family 
shifts to apoptosis induction (Nikiforov et al., 2007). It does, however, likely potentiate 
cancer cells with oncogenic c-Myc to exogenous Noxa-expression. 
The adenoviral protein E1A has oncogenic properties. However, over-expression of 
E1A in cancer activates Noxa to induce apoptosis (Flinterman et al., 2005). Oncogene 
expression was found to increase Puma levels, which did not automatically lead to cell death 
induction as Puma is bound and sequestered by pro-survival Mcl-1. Over-expression of 
Noxa releases Puma, efficiently inducing apoptosis (Nakajima & Tanaka, 2011). It is likely 
that the tumor-selectivity of Noxa is based on an oncogene-induced accumulation of inactive 






Melanoma differentiation associated gene-7 (mda-7) was found during a subtraction 
hybridization screen and expression was shown to be increased in differentiated melanoma 
cells (Jiang et al., 1995). Forced expression of mda-7 in human cancer cells induces growth 
arrest and eventually apoptosis (Su et al., 1998). Based on sequence and functional homology 
mda-7 is reclassified as IL-24, a member of the IL-10 family of cytokines (Huang et al., 2001). 
 Ectopically expressed mda-7/IL-24 localizes to the ER where it causes ER stress by 
binding, and thereby inactivating, glucose-regulated protein 78 (GRP78 or Bip) (Gupta et al., 
2006). GRP78/BiP is a chaperone and inhibition results in induction of the Unfolded 
Protein Response (UPR) (Dash et al., 2010a). Remarkably, GRP78/BiP participates as a 
cellular membrane receptor in a signaling function in Par-4 mediated apoptosis induction, as 
described below. 
 Mda-7/IL-24 can shift the balance between anti- and pro-apoptotic family members 
of Bcl-2 towards cell death (see box 2.6). Expression of mda-7/IL-24 leads to down 
regulation of Mcl-1, triggering apoptosis possibly via the same mechanism as Noxa over-
expression (Dash et al, 2010b). Apart from stimulating pro-death signaling mda-7/IL-24 
triggers apoptosis through various other pathways. Mda-7/IL-24 blocks pro-survival 
signaling by down regulating Akt expression and increasing cyclin-dependent kinase 
inhibitors (Valero et al, 2011). Furthermore, mda-7/IL-24 expression leads to increased 
ceramide accumulation and ROS (reactive oxygen species) production (Dash et al, 2010a). 
 Although there is a lot of information on the downstream cell death inducing 
properties of mda-7/IL-24, very little is known about what the tumor processes are that sets 
it off in cancer cells in the first place. Mda-7/IL-24 can activate the Fas/TRAIL pathway 
(Ekmekcioglu et al., 2008), possibly using the latter’s tumor-specific qualities to enhance its 
own. 
Exogenous mda-7/IL-24 expression can create a bystander killing effect by tumor- 
selectively increasing endogenous mda-7/IL-24 expression and secretion (Sauane et al., 
2008). Furthermore, temporary externally induced mda-7/IL-24 expression can confer 
cancer immunity upon immune competent mice (Miyahara et al, 2006). Interestingly, the 
mouse homologue of mda-7/IL-24 was found to have no anti-tumor effects (Nagakawa et 
al., 2012). 
 





The tumor suppressor prostate apoptosis response-4 (Par-4) is down regulated in many 
cancers by various mechanisms such as promoter methylation and mutations (Shresta-
Bhattarai & Rangnekar, 2010). Furthermore Par-4 expression is suppressed by oncogenic Ras 
and hTERT, aiding tumorigenesis (Sheng et al., 2010). Ectopic expression of Par-4 can block 
Ras-induced transformation (Qiu et al., 1999). Additionally over-expression of Par-4 
selectively induces apoptosis in tumor cells (El-Guendy et al., 2003). The Par-4 gene is a pro-
apoptotic gene induced after calcium-stress or androgen ablation (Sells et al., 1994). 
Apart from tumor-specific nuclear translocation needed for apoptosis induction by 
Par-4, its selectivity is stored in the ‘selective for apoptosis induction cancer cells’ (SAC) 
domain. Protein Kinase A (PKA) activates Par-4 by phosphorylating T155 in the SAC 
domain (Gurumurthy et al., 2005). Par-4 can be phosphorylated on several sites by other 
kinases. Phosphorylation by Akt renders Par-4 inactive which is needed for cancer cell 
survival (Goswami et al., 2005). Interestingly active Par-4 inhibits Akt through Protein 
Kinase C ζ (PKCζ) (Joshi et al., 2008). In the nucleus active Par-4 inhibits NF-κB activity 
leading to cell death (El-Guendy et al., 2003). 
Par-4 is secreted and induces apoptosis through the extrinsic pathway. GRP78/BiP 
normally resides in the ER. Upon ER stress it translocates to the cellular membrane where it 
functions as a receptor for Par-4. Par-4 bound to receptor GRP78/BiP recruits and activates 
caspase 8, mediating caspase 3 apoptosis induction (Burikhanov et al., 2009). GRP78/BiP is 
over-expressed at the cell surface of tumor cells (Sato et al., 2010). 
Elevated levels of PKA and GRP78/BiP in cancer cells confer upon Par-4 its tumor-
selective potential (Hebbar et al., 2012). TRAIL and Par-4 can further sensitize cancer cells 
for one another by inducing ER stress and increasing Par-4 secretion and GRP78/BiP 
surface expression (Hart & El-Deiry, 2009). 
 
ORCTL3 
In 2009 a screen was performed to identify genes with tumor-specific cell death inducing 
properties; up till then the discovery of the cancer-selectivity of PKTCs had been 
opportunistic. The organic cation transporter-like 3 (ORCTL3) was found to induce 
apoptosis in RAS-transformed cells, having no effect on their isogenic counterparts (Irshad 





cation transporter function of the protein. In several human cancers the expression of the 
ORCTL3 gene is repressed (Irshad et al., 2009). 
 
(Pre)clinical trials 
None of the PKTCs has yet been approved as anti-cancer treatment. Clinical trials are under 
way for TRAIL, HAMLET, mda-7, NS1 and onconase. As for preclinical trials, almost all 
PKTCs have shown anti-neoplastic activity in animal models with no noted negative side 
effects. No trials or animal model testing have yet been reported with brevinin-2R or 
ORCTL3.  
 Apoptin has been shown to successfully inhibit tumor growth in various mouse 
models. A wide range of delivery methods is under development. Protein therapy in which 
apoptin is coupled to a modified HIV transduction domain, PTD4, effectively treated 
various xenografts (Sun et al., 2009). Together with dacarbazine PTD4-apoptin greatly 
reduced the hematologic side effects of dacarbazine without reducing the antitumor activity 
(Jin et al., 2011). Other successful in vivo delivery methods are based on viral (Zhang et al., 
2012) or bacterial gene delivery (Cao et al., 2010). A fusion construct of E4orf4 with 
epidermal growth factor (EGF) allows internalization of E4orf4 especially in EGF receptor 
over-expressing cancer cells. This protein construct was used with no toxic side effect in a 
nude mice model (Zhou et al., 2009). The oncolytic parvovirus, encoding NS1, is effective 
against cancer development in several mouse models. The tumor-specific cell death 
induction, safety and in vitro observed immunomodulation effect are currently being tested 
in a phase I trial with glioblastoma patients (Rommelaere et al., 2010). 
 Noxa, expressed through an adenoviral vector, is effective in breast cancer xenografs 
(Suzuki et al., 2009). Furthermore, stabilization of endogenous Noxa is involved in the anti-
cancer effect of several other drugs currently under testing as for example bortezomib 
(Ohshima-Hosoyama et al., 2011). Par-4 can be secreted and elicits its effect through 
membrane receptor binding, eliminating the problem of getting the drug into the cell. Par-
4/SAC transgenic mice are resistant to the growth of oncogene-induced tumors. 
Interestingly bone marrow transplantation from these resistant transgenic mice to cancer-
susceptible mice confers tumor resistance (Zhao et al., 2011).  
HAMLET has been used in two phase I clinical trials, one showing a lasting effect 
on skin papillomas, and another in which HAMLET caused the shredding of bladder cancer 




cells. In both trials no negative effect on healthy cells was observed (Gustafsson et al., 2004; 
Mossberg et al., 2007).  Mda-7/IL-24 delivery through modified adenoviral vectors improves 
its efficiency in xenografted mice (Dash et al., 2010a). Several phase I trials with adenovirus 
vector ad.Mda-7 expressing Mda-7 showed efficient specific apoptosis induction in tumor 
cells with low toxicity. Trials support the bystander effect, triggering surrounding cells to 
start producing Mda-7/IL-24 (Eager et al., 2008). TRAIL and antibodies against the DR4 
and DR5 receptor have been used in a number of clinical trials with differing outcomes. 
Several mechanisms of TRAIL resistance have been identified. Accurate in advance 
characterization of cancer types will help to design combination therapies in which the use of 
TRAIL can add to a positive outcome (Dimberg et al., 2012). Finally, onconase has been 
enrolled in several phase I and II trials. Promising results in patients who had shown no 
response to chemotherapy led to the start of phase III trials (Constanzi et al., 2005). 
Onconase is currently in a phase IIIb confirmatory clinical trial for the treatment of 
unresectable malignant mesothelioma after an efficacy and safety assessment had been done 
(Rybak et al., 2009).  
 
Concluding remarks 
Cancer is derived from our own cells. This makes it difficult to target tumor cells without 
harming the normal cells from which they originated. However, the special features acquired 
by evolving neoplasia can be grouped and denominated. These hallmarks of cancer set the 
tumor enough apart from healthy tissue to define therapeutic targets. A group of proteins, 
PKTCs, have been shown to induce programmed cell death pathways selectively in tumor 
cells without damaging the healthy tissue. There are many different triggers in cancer cells 
that can activate a PKTC, and the method by which an activated PKTC pushes the tumor 
cell to commit suicide also varies.  
In this thesis we continue the search for features that set tumor cells apart from 
normal cells, making them vulnerable for apoptin-induced cell death. Various tumor-related 
processes that are of importance for the tumor-selective activation of apoptin are reported. 
They range from proteasome activity and mitosis regulation up to protein kinases and 
phosphatase action. The differences observed among PKTC activation and functioning 
suggests that they may complement each other during therapy. The overlap in their 
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Apoptin harbors tumor-selective characteristics making it a potential safe and effective 
anticancer agent. Apoptin becomes phosphorylated and induces apoptosis in a large panel of 
human tumor but not normal cells. Here, we used an in vitro oncogenic transformation 
assay to explore minimal cellular factors required for the activation of apoptin. Flag-apoptin 
was introduced into normal fibroblasts together with the transforming SV40 LT and ST 
antigens. We found that nuclear expression of SV40 ST in normal cells was sufficient to 
induce phosphorylation of apoptin. Mutational analysis showed that mutations disrupting the 
binding of ST to protein phosphatase 2A (PP2A) counteracted this effect. Knock-down of 
the ST-interacting PP2A B56γ subunit in normal fibroblasts mimicked the effect of nuclear 
ST expression, resulting in induction of apoptin phosphorylation. The same effect was 
observed upon down-regulation of the PP2A B56δ subunit, which is targeted by PKA. 
Apoptin interacts with the PKA-associating protein BCA3 (AKIP1), and inhibition of PKA 
in tumor cells by treatment with H89 increased the phosphorylation of apoptin, whereas the 
PKA activator cAMP partially reduced it. We infer that inactivation of PP2A, in particular of 
the B56γ and B56δ subunits, is a crucial step in triggering apoptin-induced tumor-selective 
cell death.  





Tumor formation occurs due to a complex set of processes roughly based on enhanced 
survival and limited cell death activities (Wenner, 2010). Remarkably, a set of viral and 
cellular proteins has been found to selectively induce cell death in tumor cells (Bruno et al., 
2009).  Among these proteins is the avian virus protein apoptin, which has been shown to 
induce p53-independent apoptosis in a broad spectrum of human transformed cells 
(Backendorf et al., 2008). Recent preclinical studies demonstrated the therapeutic potential 
of apoptin as a safe and efficient anticancer agent (Grimm and Noteborn, 2010). Therefore, 
it is of interest to study the mechanisms underlying apoptin-induced apoptosis, particularly 
the ‘switch’ responsible for its activation during oncogenic transformation.  
SV40 T antigens are known to be involved in oncogenic transformation through 
interference with many cellular processes (Pipas, 2009). Distinct domains on LT that bind 
and inactivate tumor suppressors p53 and Rb, have long been known to play crucial roles in 
tumor formation (Hahn et al., 1999). The SV40 ST protein enforces transformation of 
normal cells via inhibition of protein phosphatase 2A (Sablina et al., 2008; Chen et al., 2007; 
Cho et al., 2007).  
This feature is in accordance with the reduced PP2A levels found in various human 
tumor cell types (Sablina and Hahn, 2008), and accumulating evidence supporting major 
tumor suppressive roles for PP2A (Westermarck and Hahn, 2008). Another major cellular 
regulator implicated in carcinogenesis is protein kinase A (PKA) (Naviglio et al., 2009). Its 
targets include PP2A (Usui et al., 1998), and for instance, the PKA interacting protein Breast 
Cancer-associated gene 3 (BCA3) is known to be highly expressed in breast and prostate 
cancer cells compared to the normal surrounding tissue (Kitching et al., 2003).   
In this study, we investigated the minimal steps leading to the activation of apoptin 
upon malignant transformation. We previously showed that transient expression of the SV40 
large and small T antigens in normal human fibroblasts results in activation of apoptin, 
displaying all three of its characteristic features, namely phosphorylation, nuclear localization, 
and apoptosis (Zhang et al., 2004). This finding provided us with an elegant tool to analyze 
which domains of the SV40 large and/or small T antigens are responsible for this activity. In 
parallel, BCA3 was identified as an apoptin-interacting protein, and the effects of PKA on 
apoptin phosphorylation were examined. Analysis of both transformation-related pathways 






Transient expression of N-terminal SV40 LT136/ST activates apoptin in normal 
human fibroblasts  
Apoptin activity can be induced in normal cells by transient expression of transforming 
SV40 antigens (Zhang et al., 2004). Hence we examined the minimal SV40 domains 
responsible for this effect. Expression of the SV40 LT136/ST DNA sequence results, due to 
alternative splicing, in 2 proteins: LT136, comprising the N-terminal 136 a.a. of LT, and the 
entire ST protein, consisting of 174 amino acids (Figure 3.1A) (Srinivasan et al., 1997). 
LT136 contains a DNA J domain, an Rb-binding site and a nuclear localization signal (NLS). 
ST shares its DNA J domain with LT136, but has a unique C-terminal domain encompassing 
a PP2A binding site (Pipas, 2009).  
In normal human foreskin fibroblasts, co-transfection of the SV40 LT136 and ST 
proteins with Flag-tagged apoptin resulted in the latter’s phosphorylation (Figure 3.1B). 
Immunofluorescence analysis of F9 cells expressing all three proteins showed that Flag-
apoptin became nuclear already 1 day after transfection. Nuclear Flag-apoptin was also 
shown to be phosphorylated (Figure 3.1C), and 3 and 5 days post transfection, apoptin was 
shown to induce apoptosis (Figure 3.1D, E). In contrast, F9 fibroblasts expressing apoptin 
alone contained mainly cytoplasmic Flag-apoptin, which was, as expected, not 
phosphorylated (Rohn and Noteborn, 2004; Alivisi et al., 2006) and did not induce apoptosis 
(Figure 3.1C-E).  
Our results clearly reveal that transient expression of LT136 and ST proteins in 
human F9 fibroblasts results in tumor-selective activation of apoptin, providing us with the 
possibility to explore which domains and respective cellular targets of LT136/ST were 
responsible for this activity. 
 
Nuclear ST triggers apoptin activation  
Next, we examined whether expression of either LT136 or ST protein alone was sufficient to 
activate apoptin phosphorylation. F9 fibroblasts were co-transfected with plasmids encoding 
Flag-tagged apoptin and either one of the following: a) pcDNA-LT136, encoding LT136, b) 
pcDNA-ST, encoding ST, c) pcDNA-LT136/ST, where both LT136 and ST are produced 
via alternative splicing, or d) pcDNA-neo, as a negative control. In each experiment, 
activation of apoptin was assayed by its phosphorylation at position T108, assessed by means  





Figure 3.1: Transient expression of N-terminal determinants of SV40 T antigens activates apoptin. (A) 
Schematic representation of the domains in SV40 LT136/ST. The J domain (a.a. 1-82) is identical in both 
LT136 and ST. The Rb binding domain and nuclear localization signal (NLS) in LT136 are also shown. ST is 
expressed by differential splicing and has a unique C-terminus, which contains the PP2A binding domain. (B) 
Human Fibroblasts (F9) were co-transfected with plasmids pcDNA-Flag-apoptin and pcDNA-LT136/ST 
(LT136/ST) or pcDNA-neo (neo) by AMAXA nucleofector transfection. Twenty-four hours post-transfection, 
cells were lysed for Western blot analysis with the indicated antibodies. Mock-transfected F9 cells were used as 
control. Antibody α-108-P specifically recognizes phospho-apoptin at its Thr108. Flag-apoptin, LT and ST 
show the respective total protein amounts in the transfected cells. Actin was used as loading control. (C-E). 
Cells were fixed for immunofluorescence analysis at each given time point after transfection and then stained 







of Western blotting. Expression of LT136 alone did not trigger apoptin phosphorylation, 
whereas expression of ST clearly induced apoptin phosphorylation, albeit at a low level 
(Figure 3.2). Co-transfection of Flag-tagged apoptin with ST fused to an artificial nuclear 




Figure 3.2: Nuclear targeting of SV40 ST activates 
apoptin. In normal human fibroblasts, apoptin was 
co-transfected with vector only (Neo), LT136, ST, or 
both LT136 and ST. Twenty-four hours post-
transfection, cells were lysed for Western blot analysis 
with the antibodies indicated. The relative amount of 
phosphorylated (as compared to the total amount of 
apoptin) was quantified and is indicated below the a-
108-P panel. The LT136 + ST sample was set at 100.   
 
  
C103S and P101A point mutations within the PP2A-binding domain of ST disable 
activation of apoptin  
Besides its J domain, shared with LT136, ST contains a unique site for the binding and 
inactivation of PP2A. This domain has been shown to contribute to cellular transformation 
(Pipas, 2009). A single amino-acid mutation C103S within the ST protein drastically 
diminishes the interaction of ST with PP2A (Figure 3.3C) and its transforming capacity 
(Mungre et al., 1994). Therefore, we studied the effect of the C103S mutation within the 
PP2A binding site on the activation of apoptin by (nuclear) ST in normal human cells.  
F9 cells were analyzed for phosphorylation of Flag-apoptin upon co-expression with 
ST, NLS-ST or NLS-ST(C103S) protein. Figure 3.3B shows that expression of NLS-ST 
clearly induced apoptin phosphorylation.  Introduction of the NLS-ST(C103S) mutation 
abolished this induction, although apoptin protein was expressed at a similar level. Similar 
results were obtained with the NLS-ST-(P101A) mutant (Figure 3.3B). The P101A point 
mutation within ST is also known to disturb the ST-PP2A interaction and transforming 
capacity of ST (Mungre et al., 1994). These results suggest that ST interaction with PP2A is 




crucial to apoptin activation, and that inactivation of PP2A by ST might be sufficient to 
activate apoptin. 
  
Figure 3.3: Apoptin activation via ST-mediated inhibition of PP2A. (A) pcDNA-Flag-apoptin was co-
transfected with plasmids encoding the indicated proteins or vector DNA into F9 primary fibroblasts. Western 
blot assays were performed with the indicated antibodies at 24h post-transfection. (B) F9 primary cells were co-
transfected with pcDNA-Flag-apoptin and plasmids encoding NLS-ST, NLS-ST(P101A), NLS-ST(C103S) or 
vector DNA as indicated. Western blot assays were performed with the indicated antibodies at 24h post-
transfection. In panels A and B the relative percentage of phosphorylated apoptin in the various samples was 
quantified and is indicated below the a-108-P panel (C) PP2A binding to ST is abolished by C103S mutation. 
LT136 and ST with or without the C103S mutation (LT136/ST or LT136/ST(C103S) were fused with a Strep-
tag at their N-terminus. Cell lysates were prepared at 24h post-transfection for protein-protein interaction 
assays as indicated in Material and Methods. The final elutions were analyzed by Western Blot with antibodies 
against PP2A α subunit, LT and ST, respectively. Actin was taken as equal loading control. The first lane (input 
control) indicated total amount of endogenous proteins in cell lysates.  
   
Knock-down of PP2A B56γ via RNAi activates apoptin phosphorylation in normal 
human fibroblasts  
Two independent studies reported that ST interaction with PP2A resulted in the inhibition 
of the B56γ regulatory subunit, resulting in cellular transformation (Chen et al., 2007; Cho et 
al., 2007). Therefore, we examined whether down-regulation of B56γ via RNAi could trigger 





ectopic expression of B56γ (Figure 3.4A). Normal F9 fibroblasts co-expressing both apoptin 
and shRNA directed against B56γ mRNA manifested a clear level of phosphorylated apoptin 
in comparison to the cells transfected with apoptin and the RNAi control vector (Figure 
3.4C). Our data thus indicate that inhibition of the PP2A-B56γ subunit is a crucial and 
sufficient step for apoptin activation. 
 
Figure 3.4: Knock-down of PP2A B56γ and B56δ subunits triggers apoptin phosphorylation in normal cells. 
(A) Down-regulation of PP2A B56γ subunit by shRNA. HeLa cells were co-transfected with pCEP-4HA-B56γ 
expressing 4HA-tagged B56γ, and either shB56γ or control pSuper vector and lysed 48h post-transfection, 
followed by Western blotting analysis with the indicated antibodies. (B) Down-regulation of PP2A B56δ 
subunit by shRNA. F9 cells were transfected with pSuper vector encoding shRNA directed against PP2A B56δ 
or pSuper vector control; 24h post-transfection, cell lysates were prepared and subsequently analyzed by 
Western blot. (C) F9 cells were co-transfected with Flag-apoptin and either pSuper vector encoding shRNA 
directed against PP2A B56γ, δ or control; 24-48h post-transfection, cell lysates were prepared and subsequently 
analyzed by Western blot. 
 
Overexpression of PKA-interacting protein BCA3 stimulates apoptin activity in 
tumor cells  
Analogous to the enhancing effect of ST on apoptin phosphorylation in normal cells, we 
observed an enhancement of apoptin phosphorylation in tumor cells by BCA3. BCA3 was 
identified as an apoptin-interacting protein by means of a yeast two-hybrid assay, and 
interacts with apoptin in a human cellular background (Figure 3.5A). Co-expression of BCA3 
and Flag-apoptin in human Saos-2 tumor cells resulted in a significant increase in the 
apoptosis activity of apoptin (Figure 3.5B). In fact, as early as 6 hours after transfection, 
phosphorylated apoptin could readily be detected in Saos-2 cells expressing both apoptin 
and BCA3, whereas in cells expressing apoptin alone (control), apoptin phosphorylation was 
not yet visible at this early time-point (Figure 3.5C).  
As BCA3 (Westermarck and Hahn, 2008) has been shown to interact with the 
catalytic subunit of PKA (Sastri et al., 2005), the involvement of PKA in apoptin 
phosphorylation was investigated. Treatment of Saos-2 cells with H89, a known PKA 




inhibitor (Lochner and Moolman, 2006), enhanced apoptin phosphorylation. In contrast, 
addition of the PKA activator cAMP (Bulun and Simpson, 2008) diminished apoptin 
phosphorylation (Figure 3.5D). These results suggest that interference with PKA activity 
favors activation of apoptin. By taking into account the fact that the B56δ subunit of PP2A 
has been shown to be targeted by PKA (Ahn et al., 2007), we proved that this is also the case 
in our cellular system. Indeed H89 treatment of Saos-2 cells decreased the level of active 
serine-phosphorylated B56δ, whereas cAMP enhanced the amount of active B56δ (Figure 
3.5E-G). 
 
Down-regulation of PP2A-B56δ subunit activates apoptin phosphorylation in normal 
cells  
The experiments described above indicate that in cancer cells an inverse relation exists 
between the activity of PP2A-B56δ, as judged by its phosphorylation (Ahn et al., 2007), and 
the potential of apoptin to become phosphorylated in the same cells. For this reason it was 
interesting to examine whether inhibition of the expression of the PP2A-B56δ subunit in 
human F9 cells would positively affect the phosphorylation of apoptin. Down-regulation of 
B56δ protein expression through RNAi was confirmed in normal F9 fibroblasts (Figure 
3.4B). Co-expression of shRNA targeting B56δ mRNA together with apoptin in normal F9 
cells clearly resulted in the activation of apoptin phosphorylation, as compared to F9 cells 
transfected with apoptin and the RNAi control vector (Figure 3.4C).  
In conclusion, our results imply that PP2A complexes containing the regulatory 
subunits B56 δ and γ are essential for maintaining a normal cell environment, as the loss of 
either one of these subunits results in the activation of apoptin.  
 
Discussion 
Activation of tumor-selective apoptosis-inducing proteins is an intriguing phenomenon and 
revealing the molecular switch behind this process could allow important insights for 
developing anticancer therapies. Apoptin was the first protein known to harbor apoptosis 
activity selectively in transformed human cells (Bruno et al., 2009). However, the molecular 
mechanisms underlying apoptin’s tumor-selective activity are largely unknown (Grimm and 







Figure 3.5: BCA3 interacts with apoptin and stimulates its 
activity. (A) Apoptin interacts with BCA3 in a cellular 
background. Normal human foreskin fibroblasts were 
transfected with plasmids encoding myc-tagged BCA3 
and Flag-tagged apoptin, or control plasmid in the 
indicated combinations. Total lysates (L) or protein 
complexes immunoprecipitated (IP) with antibody 
against the myc- (left panel) or Flag-tags (right panel) 
were separated by SDS-PAGE and analyzed by Western 
blot. (B) Expression of myc-BCA3 together with Flag-
apoptin results in increased induction of apoptosis. 
Human Saos-2 tumor cells were transfected with 
plasmids encoding Flag-tagged apoptin and myc-tagged 
BCA3, or vector control in the indicated combinations 
and grown on glass coverslips. Forty-eight hours post-
transfection, slides were fixed and stained with 
appropriate antibodies for immunofluorescence analysis. 
pMaxGFP (Amaxa) was used as a negative control. 
Apoptosis was assessed according to characteristic 
morphological changes35 following DAPI staining as 
shown in figure 1. Data are representative of 3 
independent experiments, in which at least 100 cells were 
scored. (C) Co-expression of myc-BCA3 enhances 
apoptin phosphorylation. Saos-2 cells transfected with 
BCA3 and apoptin, or apoptin alone, were lysed 6 hours 
post-transfection and analyzed for apoptin 
phosphorylation by Western blot analysis. (D) Inhibition 
of PKA results in increased apoptin phosphorylation. 
Saos-2 cells were transfected with Flag-tagged apoptin, 
and treated with the PKA inhibitor H89 (1h, 10μM) or 
activator cAMP (30 minutes, 10μM H89, followed by 30 
minutes 1mM cAMP) 24hs post-transfection. Cells were 
then lysed and their contents analyzed by Western blot 
using indicated antibodies. The relative percentage of 
phosphorylated apoptin in the various samples was 
quantified and is indicated below the a-108-P panel (E) 
Effect of PKA inhibitors/inducers on PP2A B56δ 
phosphorylation. In a first instance phosphorylated 
proteins were immuno-precipitated from Saos-2 whole 
cell lysate (WCL) with six different antibodies directed 
against phosphoserines, as described (Materials and 
Methods). Western blot was performed with antibodies 
against B56δ. The light chain signal shows equal assay 
conditions. Note that only antibody 5 detects phospho- 
B56δ.  
(F) Saos-2 cells were treated with PKA-inhibitor H89 or mock-treated and immunoprecipitated with the 
phosphoserine antibody 5 (see panel E). The amount of pulled-down B56δ was determined by Western blot 
using an antibody directed against B56δ and quantified. The amount of phospho-B56δ in the mock-treated 
cells was set at 100. (G) Saos-2 cells were treated with PKA-stimulator cAMP or mock-treated and 
immunoprecipitated with antibodies against B56δ. The amount of phosphorylated B56δ was determined by 
Western blot using the phospho-serine antibody 5 (panel E) and quantified. The amount of phospho-B56δ in 
the mock-treated cells was set at 100.    
 
 




sufficient to activate apoptin in a tumor-selective fashion. This is inferred from two 
independent lines of research. 
 In one study, we examined the effect of specific domains within the transforming 
SV40 proteins LT136 and ST on the activation of apoptin. The C-terminal PP2A-binding 
and transformation domain of ST (Pipas, 2009; Arroyo and Hahn, 2005), when targeted to 
the nucleus of normal cells, turned out to be crucial for the tumor-characteristic activation of 
apoptin. We showed that both C103S and P101A point mutations within the ST PP2A 
binding site ( (Chen et al., 2004) abrogated the phosphorylation of apoptin induced by NLS-
ST in normal human fibroblasts. RNA interference studies confirmed that inactivation of the 
B56γ protein promotes phosphorylation of apoptin in human fibroblasts. We have 
previously shown (Zhang et al., 2004) that the N-terminal J domain, which is common to 
both LT and ST (see figure 1), is involved in apoptin activation. Interestingly, since the 
completion of this work two independent groups have resolved the molecular structure of 
the SV40 ST complex with PP2A and shown that both the C-terminal PP2A binding domain 
and the N-terminal J domain are in direct contact with the A subunit of PP2A (Chen et al., 
2007; Cho et al., 2007). The structure provides a mechanism how binding of ST to the A 
subunit of PP2A displaces the B56γ subunit and as such inactivates PP2A. The results 
described in figure S1 (supplementary information) indicate that also the J domain (either 
present on LT or ST) needs to be functional in order to activate apoptin in combination with 
a functional C-terminal PP2A binding site on ST. The data strongly suggest that the J 
domain of LT can also contribute to the displacement of B56γ and the activation of apoptin 
in concert with our previous conclusions. However, the contribution of ST, which has not 
been analyzed in detail in the previous study, is essential for activating apoptin (Figure 2).          
A second line of research indicated that interference with the PP2A-B56δ subunit 
also led to the activation of apoptin. This was achieved by treating human cancer cells with 
either PKA activator or inhibitor. PKA is known to phosphorylate the B56δ subunit of 
PP2A leading to increased PP2A activity (Ahn et al., 2007). Ectopic expression of the 
apoptin- and PKA-interacting protein BCA3, or inhibition of PKA by treatment with H89 
both resulted in enhanced phosphorylation and apoptosis activity of apoptin in human 
cancer cells. Stimulation of PKA by cAMP resulted in enhanced phosphorylation of PP2A-
B56δ and a lower level of phosphorylated apoptin in Saos-2 tumor cells. On the contrary, 





phosphorylation. These data indicate that derailed PP2A activity is crucial for activating 
apoptin in accordance with the data obtained in our SV40 transformation essay. This vision 
was further highlighted by RNA interference studies showing that inhibition of the 
expression of PP2A-B56δ activated apoptin even in normal human cells.  
Our studies reveal that apoptin senses PP2A inactivation during malignant 
transformation. Interestingly, the delta and gamma subunits are the only nuclear PP2A-B56 
subunits (Chen et al., 2004), and nuclear localization is important for both SV40-T antigen 
induced cell transformation (Pipas, 2009) and apoptin-induced tumor-selective apoptosis 
(Backendorf et al., 2008). PP2A complexes containing B56δ domains prevent entry of cells 
into mitosis upon DNA damage (Visshup and Shenolikar, 2009). B56γ is also known to 
mediate dephosphorylation and stabilization of the tumor suppressor protein p53 upon 
DNA damage, inhibiting cellular proliferation and transformation (Li et al., 2007). Evidence 
has been provided that derailment of B56γ results in aberrancies in functioning of e.g. cell 
cycle and tumor suppressor proteins resulting in cell transformation (Sablina and Hahn, 2008; 
Chen et al., 2004). Many of these features are likely due to the fact that PP2A-B56 subunits 
play an essential role in the stabilization of chromosome-spindle interactions during normal 
cell division (Foley et al., 2011). In this respect it is interesting to mention that inhibition of 
Bub1, another mitotic regulator, results in nuclear translocation of apoptin in normal cells 
(Kucharski et al., 2011). Apparently apoptin can sense aberrant mitosis and the ensuing 
genetic instability (Pihan and Doxsey, 1999) or DNA damage response signalling (Kucharski 
et al., 2011).   
PP2A plays also a role in the activation of other tumor-selective apoptosis-inducing 
proteins. Besides apoptin, the adenovirus E4orf4 protein has been demonstrated to 
selectively induce apoptosis in human cancer cells. Direct interaction of E4orf4 with PP2A 
regulatory B domains is essential for the tumor-selective apoptosis activity of E4orf4. 
Interaction of E4orf4 with PP2A-B55 results in down-regulation of myc oncogene 
expression (Ben-Israel et al., 2008). In addition to SV40 ST, other viral transforming proteins 
also interact with PP2A, further accentuating its relevance in cellular transformation (Zhao 
and Elder, 2005).  
Further steps within the development of tumorigenic cells seem at least not critical 
for apoptin’s tumor-selective apoptosis characteristics. These conclusions are in accordance 
with the observations by others and ourselves that apoptin is able to induce apoptosis in a 




very broad panel of tumor types (Backendorf et al., 2008; Grimm and Noteborn, 2010; 
Maddika et al., 2006). If one assumes that tumor cells arise by a wide variety of mechanisms, 
all the while sharing a limited number of key characteristics (Hanahan and Weinberg, 2011), 
then apoptin simply needs to recognize one (or a subset) of these characteristics.  
In summary, our results show that inactivation of the nuclear PP2A B56 δ and/or γ 
subunits are sufficient to trigger apoptin’s tumor-selective apoptosis activity. PP2A provides 
a central phosphatase activity affecting many cellular signaling pathways. As derailment of 
PP2A activity is increasingly linked to oncogenic transformation, the sensing of such a 
central regulator by apoptin might provide a rationale for its efficient killing of tumor cells 
arising from a wide range of different origins.   
 
Materials and Methods 
Cell culture  
Human diploid foreskin F9 fibroblasts, isolated from neonatal foreskin, were obtained in the 
late 1980’s from Dr. M. Ponec (Dept. Dermatology, Leiden University Medical Center). Cells 
were batch-frozen after careful morphological inspection. At subsequent passages cells were 
regularly screened for their typical fibroblast-like morphological appearance. All cells used 
were below passage 15 and cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% newborn calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin 
(Invitrogen, Breda, the Netherlands). The human Saos-2 osteosarcoma and the HeLa 
cervical carcinoma cell lines were purchased from the American Type Culture Collection 
(ATCC) and cultured in the same medium as mentioned above. Cultures were regularly 
tested to ensure the absence of Mycoplasma infection. Cell morphology was regularly 
monitored to control the absence of cross-contamination. The sensitivity to apoptin is 
characteristic of the various cell types used and is regularly assessed (see below). 
 
Plasmids  
The DNA sequence encoding apoptin was synthesized by BaseClear (Leiden, the 
Netherlands) according to the apoptin sequence use by Danen-Van Oorschot et al. (2004), 
and cloned into the mammalian expression vector pcDNA3.1(+) (Invitrogen). The 
oligonucleotide fragment encoding the Flag-tag (Invitrogen) was inserted to create the 





Plasmid pRSV-TN136 encoding the first 136 N-terminal amino acids of SV40 LT, 
including the region coding for SV40 ST, was a kind gift from Dr. J.M. Pipas (Department 
of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA). From pRSV-TN136, 
we generated the pcDNA-LT136/ST plasmid, which encodes the LT136 (The N-terminally 
truncated LT fragment containing the first 1-136 aa) and full length ST. pcDNA-LT136, 
encoding LT136 only, was constructed by introducing an intron deletion disabling ST 
expression (Yamashita et al., 1990).  
pcDNA expression vectors encoding only ST sequences were derived from pRSV-
ST. pcDNA-ST encodes for ST; pcDNA-NLS-ST contains a ST fused to a nuclear 
localization signal (NLS-ST) and pcDNA-NLS-ST(C103S) and NLS-ST(P101A) mutants 
encode the N-terminal NLS-ST fusion protein containing respectively the C103S or P101A 
mutation within the PP2A binding site (Gjoerup et al., 2001). 
The sequences encoding the N-terminal 136 aa of LT together with either full-length 
ST or the C103S ST-mutant were cloned into pEXPR-IBA105 vector to generate pEXPR-
IBA105-LT136/ST and pEXPR-IBA105-LT136/STC103S, respectively. These plasmids 
expressed Strep-tagged LT136/ST or LT136/ST C103S proteins enabling interaction studies 
with PP2A (see below) (Schmidt and Skerra, 2007). pCEP-4HA-B56γ, encoding 4HA-tagged 
B56γ, was a kind gift from Dr. M. Mumby (University of Texas, USA).  
Apoptin-interacting partners were obtained by yeast two-hybrid screening and 
verified by immunoprecipitation assays in mammalian cells, as previously described by 
Danen-Van Oorschot et al. (2004) Positive clones from the yeast two-hybrid screen were 
digested with XhoI to generate cDNA fragments, and subcloned into pMT2SM-myc to 
provide the fragments with an in-frame N-terminal myc-tag. The cDNA fragment encoding 
BCA3, including the myc-tag, was subsequently cloned into pcDNA. 
 
Transfection Methods  
We used transfection reagent DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate) (Danen-van Oorschot et al., 2004) or AMAXA 
nucleofection technology in conjunction with cell type specific NucleofectorTM solution 
(Lonza, Cologne, Germany) (Rohn et al., 2002) for DNA delivery into cells. When co-
transfection or triple-transfection was performed, the ratio of each plasmid was 1:1 or 1:1:1 




(in micrograms). In addition to the analysis by Western blot, the cells were seeded on several 
glass cover slips to allow parallel analysis at the single-cell level by immunofluorescence assay. 
 
Western Blot analysis  
Cells were lysed directly in Laemmli buffer (2% SDS, 10% Glycerol, 60mM Tris-Cl [pH6.8], 
2% β-mercaptoethanol, 0.002% bromophenol blue). Cell lysates were separated by sodium 
dodecyl-sulfate-polyacrylamide gel electrophoresis, and electroblotted onto polyvinylidene 
difluoride membranes (Bio-Rad). Blots were then incubated with antibodies against 
phosphorylated-apoptin (α-108-P (Zhang et al., 2004)), Flag-apoptin (α-Flag M2, Sigma-
Aldrich), SV40 LT (PAb416, Pab419, Calbiochem), SV40 ST (Pab280, Calbiochem), PP2A 
Aα (C-20, Santa Cruz), PP2A B56γ (α-B56γ, kind gift from Dr. Marc Mumby, Health 
Science Center, University of Texas, Texas, USA), PP2A B56δ (α-B56δ, Santa Cruz, 
Heidelberg, Germany), myc-tagged BCA3 (α-myc, BD Biosciences) and actin (α-actin, Santa 
Cruz). Antibodies directed against phosphorylated serine were 1C8 (1), 4A3 (2), 4A9 (3), 
4H4 (4), 7F12 (5) and 16B4 (6); they recognize phospho-serine with various efficiencies 
depending on the surrounding amino acid motif (Enzo Life Sciences, Antwerp, Belgium). 
Horseradish peroxidase-conjugated goat antibody against rabbit or mouse immunoglobulin 
G, or rabbit antibody against goat immunoglobulin G (Sigma-Aldrich) was used as secondary 
antibody for signal detection by enhanced chemiluminescence. Films were quantified using 
Quantity One Analysis Software (Biorad). 
 
Protein interaction assays  
Detection of a possible interaction of ST or ST-C103S mutant protein with PP2A in human 
HeLa cells was performed as follows. Twenty-four hours after DNA transfection, cells were 
washed twice with phosphate buffered saline and harvested in ice-cold mild lysis buffer 
(50mM Tris [pH 7.5], 5mM EDTA, 250mM NaCl, 0.1% Triton X-100, 5 mM NaF,  1mM 
Na3VO4, 20mM beta-glycerolphosphate, and Protease Inhibitor Cocktail (Roche), followed 
by incubation on ice for 30 min. The supernatant of the lysates was prepared by 
centrifugation at 13,000 × g and 4°C for 30 min. Strep-tagged proteins and their interacting 





manufacturer’s protocol, and resolved on sodium dodecyl sulfate-polyacrylamide gel, 
followed by Western blotting analysis with appropriate antibodies.  
 
RNA interference assay  
For human PP2A B56γ, the target sequence was: 5’-GATGAACCAACGTTAGAAG-3’; for 
the PP2A B56δ two sequences were targeted 1.: 5’ GTGTGTCTCTAGCCCCCAT 3’ and 2.: 
5’ GACCATTTTGCATCGCATC 3’ (data not shown). The pSUPER vector was designated 
for shRNA plasmid constructions (Boutros and Ahringer, 2008). The amplification and 
purification of plasmids were performed as specified by manufacturer’s instruction 
(GeneService, Cambridge, UK). Cells transfected with shRNA plasmids were lysed at 24-48 
h after transfection, and then analyzed by Western blot assay as described above. 
  
Immunofluorescence assay  
Cells were grown on glass cover slips. At indicated time points after transfection, cover slips 
were first washed once with phosphate buffered saline, and subsequently fixed with 
methanol/acetone (50%/50%) for 5-10 min at room temperature. After air-drying, the slides 
were used for immunocytochemical staining or stored at -20°C for further analysis. 
Immunocytochemical staining was carried out as described by Danen-Van Oorschot et al. 
(2004). The following antibodies were used: α-108-P, a rabbit polyclonal antibody 
recognizing phosphorylated apoptin at T108 and α-Flag, a mouse monoclonal antibody 
recognizing Flag-apoptin. SV40 proteins were visualized with PAb416, a mouse monoclonal 
antibody recognizing the epitope residing in amino acids 83-128 of LT and non-reactive with 
ST or PAb280, a mouse monoclonal antibody against the C terminus of ST. The fluorescein 
isothiocyanate (FITC) or rhodamine conjugated goat antibodies (Jackson ImmunoResearch 
Laboratories) were used as secondary antibodies. Nuclei were stained with 2,4-Diamidino-2-
phenylindole (DAPI) and apoptosis was assessed according to characteristic morphological 
changes (Danen-van Oorschot et al., 2004).  
 
PKA inhibition and stimulation  
Saos-2 cells were transfected with pcDNA-Flag-apoptin and incubated 24 hours post-
transfection with 10μM H89 (Millipore) for 1 hour (PKA inhibition), or 30 minutes with 
H89 followed by incubation with 1mM cAMP (Sigma) for another 30 minutes (PKA 




stimulation). Cells were then lysed in Laemmli buffer and the cell lysates analyzed for 
apoptin phosphorylation by Western blotting. To determine the phosphorylation status of 
B56δ, cells were lysed after treatment in mild lysis buffer as described for the protein 
interaction assay with addition of PhosSTOP (Roche). After 30 minutes of incubation, cell 
lysate was obtained by 15 minutes of centrifugation at 16100 rcf at 4°C. Whole cell lysate 
was incubated 1.5 hours with antibody either against B56δ or against phosphorylated serines. 
μMACS microbeads (Miltenyi Biotech) were added for 1 hour and proteins were pulled 
down using the μMACS column system according to the manufacturer’s protocol.  Elution 
was performed using Laemmli buffer and proteins were resolved on sodium dodecyl sulfate-
polyacrylamide gel, followed by Western blotting analysis with appropriate antibodies. 
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Supplementary figure S3.1: Both J domains on LT136 or ST can contribute to the activation of apoptin. The 
effect on apoptin phosphorylation of LT136 and ST either expressed by intron splicing (LT/st construct) 
(lanes 2, 4) or individually transfected on separate plasmids (lanes 3, 5, 6, 7) into normal human fibroblast is 
presented. The transfected SV40 genes were either wild-type (lanes 2, 3) or mutated (D44N) in the J domain 
(lanes 4, 7). In lane 5 wild-type LT136 is combined with ST-D44N, whereas in lane 6 wild-type ST is 
combined with LT136-D44N. The data indicate that when the D44N mutation is present on both genes, 
apoptin is not activated. Mutation of the J domain on ST, which prevents apoptin phosphorylation (lane 7), 
can partially be compensated by a functional J domain on LT136 (lane 5). At present the molecular basis for 
this interference is not understood. The relative percentage of phosphorylated apoptin in the various samples 












Proteasomal insensitivity of apoptin in 
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The small viral protein apoptin is capable of inducing apoptosis selectively in human tumor 
cells. In normal cells apoptin localizes in the cytoplasm where it forms aggregates, becomes 
epitope-shielded and eventually degraded. By inhibiting the proteasome activity with the 
chemical inhibitors bortezomib and Ada-Ahx3L3VS apoptin levels can be stabilized in 
normal cells similar to the tumor suppressor p53 protein. In contrast, proteasome inhibition 
in tumor cells did not affect the apoptin stability while it still stabilized p53 levels. Apparently, 
apoptin is degraded by proteasomal activity in normal human cells, a process that no longer 
takes place in tumor cells. This loss of proteasomal susceptibility appears to be specific for 
apoptin.  





Apoptin is a small protein produced by Chicken Anemia Virus (CAV) that is capable of 
inducing apoptosis in human tumor cells while leaving normal cells intact (Danen-van 
Oorschot et al., 1997). In tumor cells apoptin is phosphorylated on T108 and translocates to 
the nucleus whereas in normal cells it stays in the cytoplasm in a non-phosphorylated fashion 
(Rohn et al., 2002; Backendorf et al., 2008). In normal cells, microinjected bacterially 
expressed MBP-apoptin forms in time large aggregates that after 24 hours can no longer be 
detected in an immune-fluorescence assay. The protein can still be detected by the use of 
stringent buffers and Western blot, showing that it becomes epitope-shielded. At later time 
points the protein could no longer be detected in normal cells and was eventually degraded 
(Zhang et al., 2003). This particular behavior was not observed in tumor cells.  
Zhang et al. (2003) showed that the disappearance of MBP-apoptin was not caused 
by lysosomal degradation prompting us to investigate the role of the proteasome in the 
degradation of apoptin in both normal and tumor cells. The proteasome is a multi-subunit 
protease, which is composed of a proteolytic 20S core with regulatory 19S caps. The 
proteolytic activity is contained in the β1, β2 and β5 subunits, all with their own substrate 
specificity (Hershko and Ciechanover, 1998; Murata et al., 2009).  
To study the role of the proteasome in the degradation of apoptin we used the 
proteasome inhibitors bortezomib (Cusack et al., 2001) and Ada-Ahx3L3VS (Kessler et al., 
2001) to block proteasomal degradation in cells expressing apoptin. We show that inhibition 
of the proteasome in normal cells leads to stabilization of apoptin and p53 levels, while in 
tumor cells both proteasome inhibitors affect p53 protein levels but have no influence on 
the amount of apoptin protein.  
 
Results  
Apoptin is degraded in normal human fibroblasts 
In order to analyze a possible role of proteasomal degradation of apoptin we first examined 
the fate of apoptin levels in normal human fibroblasts ectopically expressing apoptin. After 
transfection of normal human fibroblasts with plasmid encoding flag-tagged apoptin, cells 
were fixed at various time-points and stained with antibody against the flag-tag. At 8 hours 
post transfection a diffuse apoptin distribution is observed throughout the cytoplasm. At 





(Figure 4.1A). Transfected flag-apoptin shows the same cytoplasmic localization as 
microinjected MBP-apoptin (Zhang et al., 2003). Apoptin protein levels were also analyzed 
by Western blot. Already 40 hours after transfection a drop in protein can be clearly 
observed, with hardly any to be detected three days after transfection (Figure 4.1B). This 
result indicates that apoptin likely gets degraded.  
To analyze whether this reduction in protein was due to degradation of the apoptin 
protein, the proteasome was inhibited with the proteasome inhibitor bortezomib. 
Stabilization and an actual increase in apoptin protein (1.5x) could be observed after several 
days (Figure 4.1B/C) suggesting that the decrease in apoptin levels in normal cells is due to 
proteasomal degradation. 
 
Figure 4. 1: Apoptin is degraded in time in normal cells, a process that can be blocked by bortezomib. Normal 
human fibroblasts F44 were transfected with plasmid encoding flag-tagged apoptin. (A) Cells were fixed 8, 24, 
48 and 72 hours post transfection. Flag-tagged apoptin was stained with a flag-specific antibody conjugated to 
rhodamine (red) and DNA was detected with Hoechst (blue). Apoptin appears in the cytoplasm as fine 
particles (8h), gradual clusters (24h), increased aggregates (48h) and eventually becomes degraded (72h). (B) 
Sixteen hours post transfection 0 or 60nM bortezomib was added to the cells and at three time points after 
addition cells were lysed. Total apoptin levels were determined by Western blot analysis with anti-flag antibody. 
(C) The relative amount of apoptin (as compared to t=0) with and without bortezomib was quantified and 
plotted. 
 
Bortezomib and Ada-Ahx3L3VS inhibit apoptin and p53 degradation equally in 
normal human fibroblasts 
Next, we analyzed whether besides apoptin a protein known to be degraded by the 
proteasome, i.e., tumor suppressor protein p53, can be stabilized by bortezomib with similar 
kinetics as apoptin in normal human fibroblasts. To that end, 16 hours after transfection 
increasing amounts of bortezomib were added to human normal fibroblasts expressing 
ectopic apoptin and endogenous p53. Twenty-four hours after the addition of bortezomib 
the cells were lysed and analyzed for apoptin and p53 levels by means of Western blot. A 




gradual raise of apoptin protein levels could be observed as the concentration of bortezomib 
increased (Figure 4.2A, up to ~7.5x increase compared to control). The increase in the 
amount of apoptin was mimicked by the level of p53 (Figure 4.2B, up to ~7.5x increase 
compared to control).  
As bortezomib mainly inhibits the β5 subunit of the proteasome (Kisselev et al., 
2006) we also examined the broad-spectrum proteasome inhibitor Ada-Ahx3L3VS (Kessler et 
al., 2001) in a similar experiment. This led to a stabilization of both apoptin and p53 levels 
(Figure 4.2), however, not to higher levels than observed with bortezomib (compare Figure 
4.2A/B, ~7.5x increase with bortezomib compared to a ~4x increase of flag-apoptin signal 
with Ada-Ahx3L3VS).  
Our results based on two different proteasomal inhibitors indicate that apoptin is 
degraded in normal human cells via the proteasomal pathway.  
 
Figure 4.2: Proteasome inhibitors stabilize apoptin and p53 in normal cells. Normal human fibroblasts F44 
were transfected with plasmid encoding flag-tagged apoptin. (A) 16 hours post transfection increasing 
concentrations of bortezomib or (B) Ada-Ahx3L3VS were added and 24 hours later cells were lysed. Total levels 
of apoptin and p53 were determined by Western blot analysis. The relative amounts of apoptin and p53 
(relative to the untreated signal) were quantified and are indicated below the corresponding panels.  
 
Bortezomib inhibits phosphorylation-deficient apoptin mutant protein with similar 
kinetics as p53 in normal human cells 
Apoptin induces apoptosis in tumor cells. This complicates the study of proteasomal 
breakdown in tumor cells. The phosphorylation of apoptin in cancer cells is closely linked to 
its apoptotic potential. Removal of the phosphorylation site T108 and the adjoining 
threonines greatly reduces the cell death potential of apoptin (Rohn et al., 2005). Therefore, 
we used the flag-apoptin(5Ala)106 mutant in which the stretch from position 106 to 110 has 
been replaced by alanines (Danen-van Oorschot et al., 2004). 
Normal human fibroblasts transfected with plasmid encoding this apoptin(5Ala)106 
mutant showed high protein expression at early time points, but as for the wild-type apoptin 
(Figure 4.1B/C), the apoptin(5Ala)106 mutant protein level diminished in time (Figure 4.3A). 





(Figure 4.3A). Increasing concentrations of bortezomib resulted in more apoptin(5Ala)106 
protein (Figure 3B, almost 3x increase).  
The similar kinetics of degradation of the phosphorylation-deficient mutant 
compared to wild-type apoptin in normal cells makes it an appropriate construct to study the 
degradation characteristics of apoptin in human tumor cells. P53 stabilization showed similar 
kinetics as in the wild-type apoptin experiment. 
 
Figure 4.3: Apoptin(5Ala)106 is degraded in 
normal cells in a similar fashion as p53 and 
apoptin. Normal human fibroblasts F44 
were transfected with plasmid encoding 
flag-tagged apoptin(5Ala)106 mutant. 16 
hours post transfection bortezomib was 
added. (A) At various time points cells were 
lysed and total apoptin was determined by 
Western blot analysis. (B) 24 hours after 
addition of increasing concentrations of 
bortezomib total apoptin and p53 were 
determined by Western blot. The relative 
amounts of apoptin and p53 (relative to the 
untreated signal) were quantified and are 
indicated below the corresponding panels.  
 
Bortezomib and Ada-Ahx3L3VS stabilize p53 but not apoptin(5Ala)106 in human 
osteosarcoma cells 
To examine the behavior of apoptin protein upon a bortezomib or Ada-Ahx3L3VS treatment 
in tumor cells, human osteosarcoma U2Os cells were used because they express wild-type 
p53 and are sensitive for apoptin-induced apoptosis (Diller et al., 1990; Zhuang et al., 1995). 
U2Os cells were transfected with plasmids encoding flag-tagged apoptin(5Ala)106 protein. 
Sixteen hours after transfection, the p53-positive human osteosarcoma cells were treated 
with increasing concentrations of bortezomib or Ada-Ahx3L3VS and the cells were lysed 24 
hours later.  
Increasing amounts of both bortezomib and Ada-Ahx3L3VS led to an increase in 
total p53 (Figure 4.4A/B). The p53 levels changed similarly as in normal cells as they 
increased 5x with bortezomib and 4x with Ada-Ahx3L3VS. This shows that the proteasome 
and the proteasomal inhibitors function in the U2Os tumor cell line. Remarkably, the 
amount of apoptin(5Ala)106 protein was not influenced by inhibition of the proteasome by 
increasing the concentrations of both bortezomib and Ada-Ahx3L3VS (Figure 4.4). In 
accordance with this finding is the observation that the basal level of apoptin protein in the 




U2Os cells without addition of inhibitor is 15x higher than in normal cells (Figure 4.4C). 
Altogether, these results show that apoptin(5Ala)106 can not become degraded by the 
proteasome in human U2Os tumor cells. 
 
Figure 4.4: Proteasome inhibitors influence p53 but not apoptin(5Ala)106 stability in tumor cells. Human 
osteosarcoma cells U2Os were transfected with plasmid encoding flag-tagged apoptin(5Ala)106. (A) 16 hours 
post transfection cells were treated with increasing concentrations of bortezomib or (B) Ada-Ahx3L3VS and 24 
hours later cells were lysed. Total amounts of apoptin and p53 were determined by Western blot analysis. The 
relative amounts of apoptin and p53 (relative to the 0nM bortezomib signal) were quantified and are indicated 
below the corresponding panels. (C) In order to make a direct comparison between the apoptin protein level in 
normal and tumor cells two representative experiments, one in normal and one in tumor cells, are visualized in 
the same chart. The relative amounts of apoptin and p53 in fig. 3B and fig. 4A were quantified relative to the 
untreated p53 levels and are plotted. 
 
Discussion 
By inhibiting the proteasome activity with the known proteasome inhibitors bortezomib and 
Ada-Ahx3L3VS, which both clearly positively affected the tumor suppressor p53 protein 
stability in normal and cancer cells, we revealed that apoptin protein is degraded in normal 
but not in tumor cells through the process of proteasomal degradation.  
  Apoptin is a potential therapeutic agent with very distinct behavioral differences 
between normal and tumor cells.  The differential proteasomal degradation of apoptin 
between normal and tumor cells will likely contribute to its selectivity. 
The tumor selective induction of apoptosis is the main feature of apoptin. This 
characteristic is preceded by the nuclear localization in cancer cells (Backendorf et al., 2008). 
In tumor cells apoptin is phosphorylated on T108, a modification that is not observed in 





with our protein degradation or stabilization measurements we developed a flag-tagged 
phosphorylation-deficient apoptin(5Ala)106 mutant that has a greatly reduced cell death 
inducing property (Rohn et al., 2005). In normal cells this mutant showed the same reaction 
to inhibition of the proteasome as did wild-type apoptin. In tumor cells, however, both the 
proteasome inhibitor bortezomib and Ada-Ahx3L3VS had no influence on the level of 
apoptin(5Ala)106, whereas the positive control p53 was clearly stabilized by the inhibition of 
the proteasome with similar kinetics as in normal cells.  
Nuclear translocation is a characteristic of apoptin in tumor cells. P53 can also 
localize to both the nucleus and cytoplasm and is degraded in both compartments (Yuan et 
al., 2010). This raises the question if the difference in degradation of apoptin is due to a 
different proteasomal activity in the nucleus. Although several different catalytic subunit 
compositions are known between cell types as described above, no distinction has yet been 
established between the subunit composition of the proteasome in the nucleus and the 
cytoplasm.   
In normal cells the highest levels of apoptin and p53 are reached with the inhibitor 
bortezomib compared to Ada-Ahx3L3VS. Bortezomib has a high affinity for the β5 
enzymatic subunit of the proteasome relative to Ada-Ahx3L3VS which has an equal effect on 
all three β subunits. Apparently it is the β5 subunit that plays a major role in both apoptin 
and p53 degradation. 
Although elevated levels of proteasome subunits have been found in some cancers, 
and proteasome inhibitors are used in the treatment of certain cancer types, a clear molecular 
difference between tumor and normal proteasome subunits has not yet been reported 
(Hoeller and Dikic, 2009; Bousquet-Dubouch et al., 2011).  
Possibly, it is not a difference in proteasome assembly that leads to the higher 
stability of apoptin in tumor cells. Some viral proteins are known to modulate (viral) protein 
stability through the proteasome (Hu et al., 1999). In this respect it is interesting to mention 
that apoptin influences the anaphase promoting complex or cyclosome (APC/C) complex.  
Teodoro et al. (2004) showed that interaction of apoptin with the APC1 subunit results in 
destabilisation of the APC/C complex. The APC/C is an upstream effector of the 
proteasome that is responsible for correct progression of the cell cycle by targeting cell cycle 
related proteins for degradation (Garcia-Higuera et al., 2008). APC/C is the main E3 ligase 
in the nucleus targeting proteins for degradation. Subunits of the APC/C are mutated in 




several cancers and are a popular target for viral proteins (Smolders and Teodoro, 2011). It is 
tempting to hypothesise that by disrupting the APC/C E3 ligase activity apoptin itself 
creates the situation that enables its stabilization. More research will, however, be needed to 
fully comprehend the molecular basis of the stable apoptin protein levels in tumor cells. 
 The tumor-selective apoptosis induction by apoptin makes it a very promising anti-
cancer agent. Here, we show a novel characteristic of apoptin. The differential proteasomal 
sensitivity likely will contribute to the application of apoptin as a safe and efficient 
therapeutic agent.  
 
Materials & Methods 
Cell culture 
The normal human diploid foreskin F44 fibroblasts, isolated from neonatal foreskin, were 
obtained in the late 1980’s from Dr. M. Ponec (Dept. Dermatology, Leiden University 
Medical Center). Cells were batch-frozen after careful morphological inspection. At 
subsequent passages cells were regularly screened for their typical fibroblast-like 
morphological appearance. F44 cells were used below passage 15 and cultured in 1:1 
Dulbecco’s Modified Eagle’s Medium : Ham’s F12 (DMEM/F12) (PAA, Colbe, Germany) 
containing 10% fetal calf serum (Thermo Scientific, Geel, Belgium), 100μg/mL penicillin, 
100μg/mL streptomycin  (Duchefa, Biochemie, Haarlem, The Netherlands) and 2mM 
glutaMAX (PAA).  The human osteosarcoma cell line U2Os was selected as it expresses 
wild-type p53 (Diller et al., 1990). U2Os cells were purchased from the American Type 
Culture Collection (ATCC, Wesel, Germany) and cultured in DMEM (PAA) containing 10% 
newborn calf serum (Thermo Scientific), 100μg/mL penicillin, 100μg/mL streptomycin  
(Duchefa) and 2mM glutaMAX (PAA). Cells were cultured at 37°C in a humidified 5% CO2 




The construction and expression of pcDNA3.1(+)flag-apoptin was previously described 
(Zimmerman et al., 2012). In short, the DNA sequence encoding apoptin was synthesized by 





Noteborn et al. (1991) and cloned into the mammalian expression vector pcDNA3.1(+) 
(Invitrogen, Breda, The Netherlands). The oligonucleotide fragment encoding the flag-tag 
(Invitrogen) was inserted to create the pcDNA3.1(+)flag-apoptin plasmid encoding apoptin 
fused with a flag-tag at its N-terminus. The phosphorylation-negative flag-apoptin(5Ala)106 
mutant was created as described in Danen-van Oorschot et al. (2004). The flag-tagged 
apoptin(5Ala)106 mutant plasmid was constructed by replacing the five amino acid stretch 
from position 106-110 by alanines in the pcDNA3.1(+)flag-apoptin construct background. 
 
Transfection method 
Cells were transfected with plasmids by using Amaxa nucleofection (Lonza AG, Cologne, 
Germany) according to the adapted manufacturer’s protocol. 106 cells were taken up in 
120μL nucleofector buffer (F44: 140mM Na2HPO4/NaH2PO4 pH 7.2, 5mM KCl, 10mM 
MgCl2 and U2Os: 90mM Na2HPO4/NaH2PO4 pH 7.2, 5mM KCl, 10mM MgCl2, 20mM 
Hepes-KOH pH 7.2), mixed with DNA, transferred to a transfection cuvet (VWR, 
Amsterdam, The Netherlands) and transfected with program U-20 or X-01 for F44 or U2Os, 
respectively. After addition of medium, cells were seeded on 6cm dishes. 
 
Inhibitor treatment 
The proteasome inhibitors bortezomib and Ada-Ahx3L3VS (a kind gift from dr. Bobby 
Florea, Leiden University, Leiden, the Netherlands) were used to block proteasomal protein 
degradation (Florea et al., 2010). The proteasome inhibitors were added to cells 16 h after 
transfection. Increasing concentrations of inhibitors were mixed with medium before 
addition to cells. After 24 h, unless otherwise indicated, cells were lysed and subjected to 
Western blot analysis. 
 
Immune fluorescence assay 
Cells grown on glass coverslips were first washed with phosphate buffered saline (PBS) at 
indicated time points after transfection and subsequently fixed at room temperature for 10 
min with 1% formaldehyde, 5 min with 100% methanol and 2 min with 80% acetone. After 
air-drying the slides were used for immunocytochemical staining. For antibody staining, the 
cells were first incubated with PBS plus 0.05% Tween 20 (PBS-Tween; Sigma Aldrich, 
Zwijndrecht, The Netherlands) plus 5% normal goat serum (NGS) (Sigma Aldrich) for 1 h. 




Next, the cells were incubated with the first antibody (1:150 monoclonal mouse-anti-flag 
antibody, Sigma Aldrich) in PBS-Tween plus 5% NGS for 2 h, washed with PBS-Tween, and 
incubated with the second antibody (1:100 rhodamine-conjugated goat-anti-rabbit antibody, 
Sanbio, Uden, the Netherlands) in PBS-Tween plus 5% NGS for 1 h. After washing with 
PBS-Tween cells were incubated 15 min with Hoechst 33358 (2μg/mL). Stained sections 
were mounted using PolyMount Mounting Media (Tebu-Bio, Heerhugowaard, The 
Netherlands) and analyzed with a fluorescence microscope (Olympus, Zoeterwoude, The 
Netherlands) with the Cell P software version 2.8 (Olympus).  
 
Western blot analysis 
Protein samples were separated on 15% SDS-PAGE gels and transferred to polyvinylidene 
fluoride membranes (Hybond-P, GE Healthcare, Hoevelaken, the Netherlands). The 
membranes were blocked with 5% non-fat milk in Tris-HCl-buffered saline containing 0.1% 
Tween-20 (Sigma Aldrich, Zwijndrecht, the Netherlands) for 1 hour at room temperature. 
Primary antibodies directed against flag (mouse monoclonal M2, 1:1000, Sigma Aldrich), p53 
(mouse monoclonal DO-1, 1:1000, Santa Cruz Biotechnology, Heidelberg, Germany) or 
actin (goat polyclonal I-19, 1:1000, Santa Cruz Biotechnology) were incubated in blocking 
buffer for 1 hour at room temperature. Peroxidase-coupled secondary antibodies (1:10.000) 
were obtained from Jackson ImmunoResearch Laboratories, Suffolk, UK, and membranes 
were incubated for 1 h at room temperature. Detection was achieved with enhanced 
chemiluminescence. Films were quantified using Quantity One Analysis Software (Biorad, 
Veenendaal, the Netherlands). 
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Apoptin, a protein derived from chicken anemia virus (CAV), induces apoptosis 
selectively in human tumor cells as compared to normal cells. This activity depends 
on phosphorylation and relocation of apoptin to the nucleus of cancer cells. Here, we 
describe an in vitro kinase assay that allows the biochemical characterization of 
apoptin-kinase activity in tumor cells. The kinase phosphorylates apoptin in a strictly 
ATP-dependent fashion and in a broad salt range. The kinase activity is present 
constitutively in both cytoplasm and nucleus of various human tumor cells. Q-
column chromatography showed that both cytoplasmic and nuclear fractions have 
identical fractionation characteristics, suggesting that the same kinase is present in 
both cellular compartments. Kinase activity derived from positive Q-column 
fractions bound to amylose-MBP-apoptin and could be eluted with ATP only in the 
presence of the co-factor Mg2+. Apparently, unphosphorylated apoptin interacts with 
the kinase and is released only after phosphorylation has occurred, proving that our 
assay recognizes the genuine apoptin-kinase. This is further corroborated by the 
finding that apoptin is phosphorylated in vitro at position Thr-108 and Thr-107, in 
concert with earlier in vivo observations. Our assay excludes CDK2 and PKC-β, previously 
nominated by two separate studies as being the genuine apoptin kinase.  






The chicken anemia virus derived protein apoptin induces apoptosis in tumor cells in vitro 
and in vivo, but not in normal cells (Backendorf et al., 2008; Noteborn, 2009b). Besides 
apoptin, a steadily extending group of diverse proteins which display the same remarkable 
tumor-selective apoptosis activities has been identified (Bruno et al., 2009; Grimm & 
Noteborn, 2010; Pavet et al., 2011). These proteins are potential therapeutics for the 
treatment of cancers, as they appear to recognize tumor-related processes resulting in the 
induction of apoptosis (Noteborn, 2009b; Tavassoli et al., 2005; Maddika et al., 2006). 
 Apoptin harbors two apoptosis-inducing death-domains which function in an 
additive manner (Backendorf et al., 2008; Danen-van Oorschot et al., 2003). The N-terminal 
domain has not been extensively explored but contains a protein-multimerization domain, 
whereas the C-terminal domain contains a bipartite nuclear localization sequence (NLS, 
position 82-88 & 111-121), a nuclear export sequence (NES, position 97-105) and a 
phosphorylation site at Thr-108 (Backendorf et al., 2008). These C-terminal death-domain 
elements are collectively responsible for the major tumor-selective characteristics of apoptin.    
Several studies have indeed established that the nuclear localization and 
phosphorylation of apoptin are linked to its tumor-selective cell death potential (Rohn et al., 
2002; Lee et al., 2007). Poon et al. (2005) have proposed an elegant model for the differential 
localization of apoptin in normal and cancer cells: the NES is functional in normal cells but 
inactive in tumor cells, due to phosphorylation of T108, thus trapping the protein selectively 
in the nucleus of tumor cells. T108 is one of three consecutive threonine residues in the 
primary structure of apoptin (position 106-108) (Backendorf et al., 2008). Mutational analysis 
has indicated that a T108A mutation does only partially decrease nuclear translocation of 
apoptin in cancer cells (Poon et al., 2005; Rohn et al., 2005). For a complete inactivation of 
the C-terminal death domain of apoptin, mutation of both T108 and T107 is requested 
(Rohn et al., 2005), suggesting that phosphorylation at T107 can compensate for the loss of 
the T108 site. Nuclear import via the bipartite NLS is not inhibited by phosphorylation as 
was shown by using a T108E mutant that mimics constitutive phosphorylation of apoptin 
Rohn et al., 2002).  
The link between phosphorylation of apoptin and its nuclear localization is also 
clearly displayed in transformation assays using SV40 large T antigen (LT) (Zhang et al., 





localization and phosphorylation of apoptin. However, forced nuclear targeting of native 
apoptin in normal cells is not sufficient to induce apoptosis, showing that phosphorylation is 
an essential step in the activation of apoptin (Danen-van Oorschot et al., 2003). 
The identity of the tumor-selective kinase responsible for the phosphorylation of 
apoptin has not yet been univocally determined. As a first approach into this direction we 
have set-up an in vitro kinase assay to analyze the biochemical characteristics of apoptin-
kinase. Our studies reveal that the kinase activity can be readily detected in various human 
tumor cell lines from different origins.  This activity is strictly ATP dependent and can be 
measured in a broad salt range. It is present constitutively in cancer cells and needs no 
upstream activation step before isolation. It locates to both cytoplasm and nucleus, binds 
directly to apoptin and is released after the phosphorylation reaction has occurred. 
Recently, some confusion has occurred in the field, as two different candidates for 
apoptin kinase have been proposed by two separate groups (Maddika et al., 2009; Jiang et al., 
2010). Jiang and co-workers inferred that protein kinase C isoforms are responsible for the 
cell death activity of apoptin, whereas Maddika and colleagues argue that CDK2 is doing so. 
By using our apoptin kinase assay in combination with antibody depletion, we were able to 




In vitro apoptin is phosphorylated in an ATP-, time-, and concentration-dependent 
manner 
One of the main characteristics of apoptin is its tumor-selective phosphorylation at 
threonine 108 (Rohn et al., 2002). First, we have examined the kinetics of the apoptin kinase 
activity in an in vitro system consisting of MBP-apoptin and whole tumor cell lysate derived 
from human tumorigenic Jurkat cells with addition (or not) of ATP during different time 
intervals. Addition of ATP showed a time dependent increase in MBP-apoptin 
phosphorylation by a whole cell lysate as detected by means of Western-blot analysis using 
the phospho-specific 108P antibody (Figure 5.1A). Variation of the amount of cell lysate 
shows a kinetic linear range of the kinase activity up till 10μg of the Jurkat cell lysate (Figure 
5.1B). In the following experiments we stayed in this linear range in order to quantify and 
compare the amount of kinase activity in various samples. 






Figure 5.1: ATP and salt-dependent in vitro apoptin kinase assay. Western blot analysis of in vitro kinase assay 
samples is represented. (A) Jurkat whole cell lysate was incubated with MBP-apoptin in the absence or presence 
of ATP for different amounts of time. Samples were analyzed with antibody against apoptin phosphorylated on 
threonine 108 (108P) and antibody against MBP to ensure equal assay conditions. (B) Increasing amounts of 
Jurkat whole cell lysate were incubated for 30 min with MBP-apoptin and ATP. Phosphorylation was analyzed 
with 108P antibody and signal intensity was plotted against the amount of protein. (+) indicates background 
signal when no ATP is used in the assay. The results of one representative experiment are shown. (C) Salt 
dependency of the in vitro kinase assay: Jurkat whole cell lysate was incubated with MBP-apoptin and ATP and 
the indicated amounts of KCl. Samples were analyzed with antibody detecting apoptin phosphorylated on 
threonine 108 (108P) and antibody against MBP detecting total MBP-apoptin in the assay. 
 
Tumor-selective kinase activity of apoptin is salt inducible 
It is well known that enzyme activity and structure are influenced by the salt concentration 
of the buffer (Branden & Tooze, 1991). Therefore, we examined whether increasing KCl 
concentrations had an effect on the kinase activity in Jurkat whole cell lysates. Western-blot 
analysis showed that the tumor-selective apoptin kinase activity has a broad salt-dependence 
ranging from 50 to 400 mM KCl (Figure 5 1C). The fact that the kinase is active within such 
a broad salt range enables the use of ion exchange chromatography to enrich the kinase 
activity without inhibiting its activity. A similar activity profile was seen following addition of 
NaCl (data not shown). 
 
Apoptin kinase activity can be detected in both the cytoplasm and the nucleus 
Because nuclear location of apoptin is linked to its phosphorylation (see above) it was 
interesting to determine the cellular location of the apoptin kinase activity in tumor cells. 
Therefore we decided to separate cytoplasmic and nuclear fractions from the human tumor 
cell lines Jurkat, MCF-7, HeLa, U2OS and Saos-2. The cytoplasmic marker MEK-2 and the 
nuclear marker C23 were used as indicators for assessing the purity of the cytoplasmic and 





Figure 5.2 clearly shows that the various tumor cytoplasmic and nuclear fractions 
both can phosphorylate apoptin. The ratio of the cytoplasmic and nuclear apoptin-related 
kinase activity varies among the different tumor cell types. MCF-7 cells harbor a dominant 
nuclear activity, whereas Jurkat cells have a higher cytoplasmic activity. The other three 
analyzed tumor cell types have a more equal cytoplasmic-nuclear distribution of the 
endogenous tumor-selective kinase activity. 
 
Figure 5.2: Cellular localization of the apoptin kinase activity. Different tumor cells were lysed and both soluble 
nuclear and cytoplasmic fractions were isolated and tested for kinase activity. Phosphorylation of apoptin was 
detected by Western blot with the phosho-specific 108P antibody. 108P signal was quantified and the relative 
kinase activity in cytoplasm or nucleus is indicated (the cytoplasmic activity was set at 1). The absence of cross-
contamination between cytoplasmic and nuclear fractions was determined by using MEK2 (cytoplasmic 
marker) and C23 (nuclear marker) specific antibodies.  
 
Apoptin kinase activity is a unique kinase 
To determine whether the nuclear and cytoplasmic fractions contain the same kinase activity 
we examined Q column fractionation profiles. In Figure 5.3 a fractionation pattern of a 
Jurkat cytoplasmic lysate is shown. The activity of all fractions was tested in the in vitro 
kinase assay after samples were diluted at least 5-fold, keeping all the protein-containing 
fractions within the active salt-concentration range determined above. The kinase activity 
eluted around 350 mM KCl as a single peak with a parabolic shape (R2 = 0.994 after 
polynomial trend-line fitting), suggesting that it represents the activity of a unique kinase 
(grey curve in Figure 5.3). Fractionation of nuclear extracts of Jurkat cells resulted in an 
identical kinase activity elution pattern (data not shown), indicating that the same kinase 
activity is present in both nucleus and cytoplasm. 
 
 Apoptin associates directly with the endogenous kinase activity under in vitro 
conditions  
Whole cell lysate (Figure 5.4A) or pooled active cytoplasmic Q-column fractions (Figure 
5.4B) derived from Jurkat tumor cells were incubated with MBP-apoptin and fractionated on  






Figure 5.3: Q column purification of apoptin kinase activity. Elution profile of a cytoplasmic fraction from 
Jurkat cells (UV absorption 280nm; black curve): proteins were loaded on a Q column and fractionated by 
elution with a 0-1M KCl salt gradient (dotted line). The presence of apoptin kinase in each fraction was 
checked with the in vitro kinase assay and analyzed on Western blot with the phospho-specific antibody (108P). 
The activity signal was quantified and the relative signal was plotted (grey line). Fitting a polynomial trend-line 
gave an R-squared value of 0.994. 
 
an amylose affinity-column. Elution was performed with a buffer containing ATP. In Figure 
5.4A no activity was detected in the flow through (ft) and early wash-out (wo) fractions 
whereas eluted fractions showed clear apoptin kinase activity. In Figure 5.4B more activity 
was found in the (ft) and (wo) fractions, probably due to overload, but again the kinase was 
clearly eluted by ATP. Importantly, the kinase could not be eluted with ATP when the 
cofactor Mg2+ was left out of the elution buffer, but it was still eluted with maltose (mw) 
(Figure 5.4C). Apparently, the interaction between apoptin and the kinase is only abolished 
after the phosphorylation event took place. To ensure that the phosphorylation observed 
was the result of the in vitro kinase activity and not due to MBP-apoptin accidentally 
released from the column, representative fractions were also tested without addition of ATP 
and MBP-apoptin and shown to be negative (Figure 5.4A/B). Finally, MBP-apoptin could be 





elution fractions contained phosphorylated MBP-apoptin released from the column 
(detected in the – samples) and some residual kinase activity, which is identified due to the 
higher activity in the + samples as compared to the – samples of the mw fractions. 
 
Figure 5.4: Kinase-apoptin interaction/dissociation is phosphorylation-dependent. Jurkat whole cell lysate (A) 
or pooled active cytoplasmic fractions (B) were incubated with MBP-apoptin and loaded on an amylose 
column. Following wash-out (wo), proteins were eluted with elution buffer containing ATP and Mg2+ (elution). 
Fractions (+) were tested in vitro for kinase activity and the presence of phosphorylated apoptin was checked 
by Western blot with the phospho-specific 108P antibody. Selected fractions (-) were tested without addition of 
ATP and MBP-apoptin. On-column-phosphorylated MBP-apoptin was eluted with maltose (mw). No kinase 
activity eluted from the column when an elution buffer without Mg2+ was used (C). Flow-through fractions are 
marked (ft). 
 
Apoptin is phosphorylated on threonine 108 as well as on threonine 107 
We have mentioned above that mutating Thr-108 to an alanine does not completely abolish 
the apoptosis induction by the C-terminal death-domain of apoptin, suggesting that 
phosphorylation of the adjacent threonines at positions Thr-106 and Thr-107 might also 
occur (Rohn et al., 2005). To confirm apoptin phosphorylation on Thr-108 and potentially 
on the neighboring threonines, in vitro phosphorylated MBP-apoptin was analyzed by mass  






Figure 5.5: Mass spectrometry analysis of 
phosphorylated MBP-apoptin. MBP-apoptin was 
phosphorylated in vitro and purified on an amylose 
column. Phosphorylated protein was digested with 
trypsin and subjected to mass spectrometry analysis. 
Detail of three full mass spectrometry scans showing 
the apoptin peptide VSELKESLITTTPSRPR 
containing the triple T phosphorylation site eluting at 
different time points: (A) native peptide, (B) 
phosphorylation on threonine 107 or on (C) threonine 
108. The related mass increments of the y ion in the 
MS2 of the fragmented peptide are shown in table 1. 
 
 
Table 5.1: mass increments of the y ions in the MS2 of 
the fragmented peptide 
Apoptin 97-113 peptide was selected during the full 
mass spectrometry scan and further fragmented in the 
ion trap. Mass increase of the y ion fragments is 
shown. Bold indicates presence of HPO3. A: native 
peptide; B: peptide phosphorylated on T107; C: 





  A  B C 
Pos Seq y y y 
97 V    
98 S 87.03 87.03 87.03
99 E 129.04 129.04 129.04
100 L 113.08 113.08 113.08
101 K 128.10 128.10 128.10
102 E 129.04 129.04 129.04
103 S 87.03 87.03 87.03
104 L 113.08 113.08 113.08
105 I 113.08 113.08 113.08
106 T 101.05 101.05 101.05
107 T 101.05 181.01 101.05
108 T 101.05 101.05 181.01
109 P 97.05 97.05 97.05
110 S 87.03 87.03 87.03
111 R 156.10 156.10 156.10
112 P 97.05 97.05 97.057






spectrometry. Whole cell lysate of human tumor Saos-2 cells was used in the in vitro kinase 
assay and MBP-apoptin was purified on an amylose column. After tryptic digestion 
phosphorylated peptides were enriched on a TiO2 column. The modification on Thr-108 was 
confirmed (Figure 5.5C and table 1, column C). Additionally, a peptide with an identical m/z 
value showed a different fragmentation pattern displaying the presence of a phosphate group 
on Thr-107 (Figure 5.5B and table 1, column B). We did not obtain evidence that Thr-106 
was also significantly phosphorylated (data not shown), whereas non-phosphorylated MBP-
apoptin peptides were readily observed (Figure 5.5A and table 1, column A). 
 
Exclusion of CDK2 and PKC as genuine apoptin kinases 
Recently two separate research groups have respectively proposed CDK2 and PKC-β as the 
genuine apoptin kinase (Maddika et al., 2009; Jiang et al., 2010). As it is rather unlikely that 
these kinases which belong to completely different classes of human kinases (Manning et al., 
2002) would both be involved in apoptin phosphorylation we have used our in vitro system 
to analyze the implication of each of these kinases in apoptin phosphorylation. Saos-2 whole 
cell lysates were depleted either specifically of CDK2 or of all PKC isoforms by antibody 
pull down. The results in Figure 5.6 clearly show that both for CDK2 (panel A) and PKC 
(panel B) the kinases could be depleted from the extract but this did not result in a lower 
apoptin-kinase activity. Apparently neither CDK2 nor PKC-β (nor another member of the 
PKC kinase family) can be considered as being the genuine apoptin kinase. 
 
Figure 5.6: Western blot analysis of in vitro kinase assay samples after kinase depletion. Either CDK2 (panel 
A) or PKC (panel B) were pulled down with increasing amounts of antibody from Saos-2 whole cell lysate 
(WCL). Cleared lysates were tested for apoptin-kinase activity and the presence of the specific kinase. Actin 
was used as a loading control. 
 
Discussion 
We have set-up a robust kinase assay and identified various biochemical properties of the 
tumor-selective apoptin kinase activity. Column-fractionation of tumor lysates revealed the 
existence of a constitutive endogenous kinase activity in tumor cells, which does not need 





additional activation steps before isolation. In all analyzed tumor cells the kinase activity was 
present in both nucleus and cytoplasm, although at various ratios. 
The measured kinase activity is strictly dependent on ATP addition and is influenced 
by the salt concentration of the buffer. The kinase, present in column-chromatography 
fractions, binds to (MBP)-apoptin and is released upon ATP treatment. Absence of the Mg2+ 
co-factor prevents kinase/apoptin dissociation, illustrating that the kinase releases apoptin 
only after phosphorylation has occurred. Rohn et al. (2005) have previously reported that 
preventing phosphorylation at Thr-108 hardly affects apoptosis induction. They showed that 
both Thr-107 and Thr-108 need to be mutated in order to abolish the apoptotic activity of 
apoptin  (Rohn et al., 2005). The data presented here now prove that the kinase activity that 
is detected in our in vitro assay has indeed the ability to phosphorylate apoptin on Thr-108 
and Thr-107. Both the binding experiment and the observed phosphorylation pattern prove 
that we are dealing with the genuine apoptin kinase. 
Recently, two separate groups proposed two different kinases, CDK2 and PKC-β as 
candidates for apoptin kinase (Maddika et al., 2009; Jiang et al., 2010). However, depletion of 
either CDK2 or PKC from whole cell lysates did not affect the phosphorylation of MBP-
apoptin in our in vitro kinase assay, casting serious doubt on the role of these two kinases in 
apoptin phosphorylation. Additionally, other findings in this paper also do not support the 
models proposed by these two groups. The study of Maddika et al. (2009) predicted an 
active upstream role of apoptin in the phosphorylation and activation process. In this model, 
apoptin binds to Akt resulting in transfer of both apoptin and Akt to the nucleus and 
association with CDK2. CDK2 is then assumed to be activated by Akt and to phosphorylate 
on its turn apoptin. Our findings contrast with this model. We have demonstrated that a 
constitutive kinase activity can be isolated from cancer cells that have never been in contact 
with apoptin. Apart from this feature, the kinase activity is not limited to the nucleus, but 
can also be extracted from the cytoplasm of tumor cells. This is in line with our previous 
finding that during SV40 large T transformation of human fibroblasts phosphorylated 
apoptin can first be observed in the cytoplasm before it is seen in the nucleus at later stages 
(Zhang et al., 2004). Jiang et al. (2010) showed that phosphorylated apoptin is present in the 
cytoplasmic membrane of transfected multiple myeloma (MM1.R) cells. They indentified 
protein kinase C isoform beta (PKC-β) as the kinase that phosphorylates apoptin in MM1.R 





portion of the kinase appears to transfer to the nucleus. Again this nuclear translocation of 
the kinase activity requires the cells to have been in contact with apoptin. Both Jiang and 
Maddika used GFP-tagged apoptin, a construct that has been shown to behave in several 
aspects differently to native apoptin (Lee et al., 2007; Rohn et al., 2005). For instance, 
variations in the cellular localization in normal cells have been recorded and should caution 
against a possible deviant behavior of the recombinant protein in human tumor cells in vivo 
(Kooistra, 2007). All experiments presented here have been performed in vitro. As a 
conclusion, by taking into account the data described here, both CDK2 and PKC-β should 
no longer be regarded as being the genuine apoptin kinase. 
 Poon et al. (Poon et al., 2005) proposed that phosphorylation of T108 blocks its 
nuclear export sequence (NES) trapping the protein selectively in the nucleus of tumor cells. 
Threonine 107 localizes even closer to the NES and as such phosphorylation of this position 
is equally likely to counteract the nuclear export of apoptin. Nuclear import is not blocked 
by phosphorylation in the triple T region as was shown by the nuclear import of the T108E 
mutant in normal cells (Rohn et al., 2002) and by the localization of phosphorylated apoptin 
in SV40 large T injected fibroblasts first in the cytoplasm and later in the nucleus (Zhang et 
al., 2004). This shows that the original cellular localization of apoptin phosphorylation has 
no influence on its later cellular distribution and is in line with our finding that apoptin can 
be phosphorylated by a kinase activity isolated from different cellular compartments of 
tumor cells. 
The biochemical characterization of the kinase phosphorylating apoptin points to an 
existing constitutive endogenous kinase activity in tumor cells, which can be present in both 
the nuclear and cytoplasmic compartments. The endogenous kinase has a broad salt-
dependence range and the ability to phosphorylate apoptin on both T107 and T108. These 
biochemical characteristics need to be taken into account in order to unequivocally identify 
the genuine kinase responsible for activation of the tumor-selective apoptosis-inducing 
protein apoptin. 
 
Materials and Methods 
Cell culture 
All cells were cultured at 37°C in a humidified 5% CO2 incubator. Jurkat cells were grown in 
RPMI1640 medium, Saos-2, U2Os, MCF-7 and HeLa cells were cultured in Dulbecco’s 





modified Eagle’s medium. Both culture media were supplemented with 10% fetal calf serum, 
100µg/mL penicillin, 100µg/mL streptomycin and 2mM glutaMAX. 
 
Recombinant MBP-apoptin protein 
The cloning, expression and biophysical properties of soluble MBP-apoptin have previously 
been described (Leliveld et al., 2003b). Briefly, the construct pMalTBVP3 encoding an N-
terminally MBP-tagged recombinant apoptin protein (MBP-apoptin, 55.8kDa) was expressed 
in Escherichia coli. The MBP gene and the apoptin gene are separated by a flexible hinge 
region encoding 10 Asn residues and a thrombin cleavage site. The cleared lysate of 250mL 
bacterial culture was passed over an amylose column (GE Healthcare, Hoevelaken, The 
Netherlands), equilibrated in 20mM Tris-HCl buffer, pH 7.4, 200mM NaCl, 1mM EDTA 
and 1mM DTT at 4°C. The column was washed with equilibration buffer and then eluted 
with 20mM Tris-HCl buffer, pH 7.4, 200mM NaCl, 1mM EDTA, 1mM DTT and 10mM 
maltose. Eluate was loaded on a Highload 16/60 Superdex 200 gel filtration column (GE 
Healthcare) equilibrated in PBS, 1mM EDTA. Protein was eluted in PBS, 1mM EDTA. 
PMSF was directly added to the eluate to a final concentration of 0.5mM to prevent 
degradation by traces of E. coli proteases. Appropriate fractions were pooled and 
concentrated on an Amicon Ultra centrifugal filter unit (Millipore, Amsterdam, The 
Netherlands) with a 10,000Da cut-off. Protein solutions were never subjected to 
freeze/thawing. Stocks were kept at -20°C and a working solution of 4mg/mL at 4°C. 
 
In vitro kinase assay 
Cell cultures were suspended in in vitro kinase (IVK) buffer (10mM Tris-HCl pH 7, 10mM 
MgCl2, 10mM NaF, 100mM KCl, 2mM DTT) containing protease inhibitor cocktail 
(complete Mini, Roche) and phosphatase inhibitor cocktail (PhosSTOP, Roche, Woerden, 
The Netherlands) and lysed by freeze-thawing. Protein concentration was determined 
spectrophotometrically using the A230/A260 absorption (Kalb & Bernlohr; 1977). Equal 
amounts of whole cell lysate (WCL) or equal volumes of column fractions were incubated in 
the presence of 50µM ATP and 4µg MBP-apoptin at 30°C for 30min unless otherwise 
indicated. Reactions were stopped by addition of EDTA. Control reactions were performed 






Nuclear-cytoplasmic  fractionation 
Cellular pellets were suspended in IVK buffer and incubated on ice. After addition of NP40 
(final concentration 0.6%) cells were vortexed and centrifuged at 16,100 g for 30 s. 
Supernatant was collected as a cytoplasmic extract. The pellet was washed, resuspended in 
IVK buffer containing 400mM NaCl, supplemented with protease and phosphatase 
inhibitors, and incubated for 15 min at 4°C with regular vortexing. The supernatant, 
obtained after centrifugation at 16,100g for 15 min, was used as nuclear extract. Equal 
relative amounts of cytosolic and nuclear extract were used for the in vitro kinase assay and 
subjected to Western blot analysis. 
 
Western blot analysis 
Protein samples were separated on 12.5% SDS-page gels and transferred to polyvinylidene 
fluoride membranes (Hybond-P; GE Healthcare). The membranes were blocked with 5% 
non-fat milk in Tris-HCl-buffered saline containing 0.1% Tween-20 for 1 hour at room 
temperature. Primary antibodies directed against MBP (mouse monoclonal, 1:2000, Zymed, 
Uden, The Netherlands), MEK-2 (rabbit polyclonal, 1:2000, N-20, Santa Cruz 
Biotechnology, Heidelberg, FRG), C23 (mouse monoclonal, 1:2000, MS-3, Santa Cruz 
Biotechnology) were incubated in blocking buffer for 1 hour at room temperature. 
Membranes treated with primary antibody directed against phosphorylated apoptin (108P) 
were blocked with 3% BSA in Tris-HCl buffered saline containing 0.1% Tween-20 for 1.5 h 
at room temperature. Antibody against phosphorylated apoptin was custom made by 
Eurogentec, Maastricht, The Netherlands and produced as previously described (Danen-van 
Oorschot et al., 2003). Peroxidase-coupled secondary antibodies (1:10,000) were from 
Jackson ImmunoResearch Laboratories, Suffolk, UK, and membranes were incubated for 1 
h at room temperature. Detection was achieved with enhanced chemiluminescence. Films 




Cells were freeze-thawed in IVK buffer. WCL was cleared by centrifugation at 16,100g for 5 
min. Increasing amounts of an antibody recognizing all PKC isoforms (mouse monoclonal, 
A-9, Santa Cruz Biotechnology) or a CDK2-specific antibody (rabbit polyclonal, SC-163, 





Santa Cruz Biotechnology) were added to the WCL and incubated for 1 hour at 4°C while 
tumbling. After addition of protein G-conjugated beads (GE Healthcare) lysates were 
incubated for another hour at 4°C while tumbling. Kinase depleted lysate was obtained after 
centrifugation at 12,000g for 30 sec by collecting the supernatant. Supernatants were tested 
in the in vitro kinase assay and subjected to Western blot analysis. 
 
Column purifications 
Cells were freeze-thawed in IVK buffer. Cellular extracts were cleared by centrifugation at 
16,100g for 5 min and loaded on a resource Q column according to the manufacturer’s 
protocol (GE Healthcare). Proteins were eluted with a KCl gradient. Fractions were diluted 
at least 5 fold before monitoring kinase activity in IVK buffer in our in-vitro kinase assay. 
Positive fractions were pooled, diluted in 20mM Tris-HCl pH7.5, 1mM DTT, 100mM KCl 
and incubated with MBP-apoptin. The sample was loaded on an amylose column. Elution 
was done with 20mM Tris-HCl pH7.5, 1mM DTT, 100mM KCl, 5mM ATP, 5mM MgCl2. 
 
Mass spectroscopy 
In-vitro phosphorylated MBP-apoptin was purified by standard amylose column purification 
(see above) and precipitated with trichloroacetic acid. Pellets were resuspended in 8M urea, 
0.4M ammonium bicarbonate. Prior to digestion, proteins were reduced with 7.5mM DTT 
and alkylated with 14mM iodoacetamide. The mixture was diluted 3-fold with H2O before 
trypsin solution was added to a final concentration of 3µg/mL and incubated overnight at 
37°C. Peptides were collected and desalted on stage tips. The TiO2 chromatography was 
performed using a triple stage precolumn (Nanoseparations, Nieuwkoop, The Netherlands). 
Both TiO2 eluate and flow-through fractions were chromatographically resolved using a 10-
55% linear acetonitrile gradient. Peptides were analyzed on a LTQ-Orbitrap mass 
spectrometer (Thermo-Fischer, Breda, The Netherlands). Full-scan MS spectra were 
acquired in the Orbitrap and the three most intense ions were selected for MS/MS 
fragmentation in the linear ion trap. Sequence and phospho-site identification was performed 
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Mitotic catastrophe triggered in human 
cancer cells by the viral protein apoptin 
 
 


































Mitotic catastrophe is an oncosuppressive mechanism that senses mitotic failure leading to 
cell death or senescence. As such it protects against aneuploidy and genetic instability and its 
induction in cancer cells by exogenous agents is currently seen as a promising therapeutic 
endpoint. Apoptin, a small protein from Chicken Anemia Virus, is known for its ability to 
selectively induce cell death in human tumor cells. Here we show that apoptin triggers p53-
independent abnormal spindle formation in osteosarcoma cells. Approximately 50% of 
apoptin-positive cells displayed non-bipolar spindles, a ten-fold increase as compared to 
control cells. Besides, tumor cells expressing apoptin are greatly limited in their progress 
through anaphase and telophase and a significant drop in mitotic cells past the meta-to-
anaphase transition is observed. Time-lapse microscopy showed that mitotic osteosarcoma 
cells expressing apoptin displayed aberrant mitotic figures, had a prolonged cycling time 
during mitosis and eventually underwent cell death. We infer that apoptin triggers apoptosis 
in dividing human tumor cells through induction of mitotic catastrophe. 




Mitotic catastrophe is an oncosuppressive mechanism emerging as a promising endpoint in 
cancer treatment (Galluzzi et al., 2012; Vitale et al., 2011). Originally used as a denomination 
for ‘death during mitosis’, mitotic catastrophe reached a tentative consensus definition as a 
mechanism that senses mitotic failure resulting in an irreversible fate, such as apoptosis, 
necrosis or senescence. The aberrant mitosis can be caused either by premature or 
inappropriate entry into mitosis or a failure of related checkpoints in combination with 
cellular damage (Vitale et al., 2011; Castedo et al., 2004). Mitotic catastrophe is considered an 
oncosuppressive pathway due to its association with absent or weakened checkpoints 
(Roninson et al., 2001). It has been argued that the evasion of mitotic catastrophe constitutes 
one of the gateways to cancer development (Vitale et al., 2011). 
Apoptin is a small avian-virus derived protein capable of selectively inducing 
apoptosis in human tumor cells while having no detrimental effect on healthy normal cells 
(Backendorf et al., 2008; Argiris et al., 2011). In normal cells it localizes to the cytoplasm 
where it is efficiently degraded by the proteasome (Lanz et al., 2012b). On the contrary, in 
transformed cells apoptin is phosphorylated on threonine 108 and localizes to the nucleus 
(Rohn et al., 2002). Until now apoptin has been shown to induce apoptosis in over 70 
human cancer cell lines (Backendorf et al., 2008) and in preclinical mouse model studies 
apoptin acted as an efficient and safe anticancer therapeutic (Sun et al., 2009; Jin et al., 2011). 
Recently, we showed that the tumor-selective behavior of apoptin can be triggered in 
normal human fibroblasts by down-regulation of the B56γ or B56δ subunits of the tumor-
suppressor protein phosphatase 2A (PP2A) (Zimmerman et al., 2012). The B56-PP2A 
complex is enriched at the centromeres and centrosomes of mitotic cells and responsible for 
the formation of stable attachments between kinetochores and microtubules (Foley et al., 
2011). Inactivation of PP2A by viral oncoproteins contributes to cell transformation 
(Westermarck & Hahn, 2008) possibly by increasing the frequency of chromosomal 
instability (Foley et al., 2011). These findings raised the question whether apoptin can sense 
chromosomal instability and perturb spindle formation during mitosis. 
To this end we examined the impact of ectopically expressed apoptin on the mitotic 
process in human osteosarcoma cells (either Saos-2: p53-null cells (Masuda et al., 1987) or 
U2Os: p53-wild type cells (Diller et al., 1990). Cells were transiently transfected with plasmid 
encoding either flag-apoptin or flag-SPRR4, a skin cornification protein (Cabral et al., 2001) 





Figure S6.1). Both apoptin-positive and apoptin-negative mitotic cells within the same 
transfected dish were scored for normal/abnormal bipolar spindle formation. The data 
demonstrate that apoptin expression caused an increase in abnormal spindle formation in 
mitotic cells which was not observed in non-transfected cells in the same dish or in SPRR4-
transfected cells (Figure 6.1). No difference was observed between Saos-2 (Figure 6.1A-G) 
and U2Os cells (Figure 6.1H-N). Apparently, the effect exerted by apoptin during mitosis in 
cancer cells is not dependent on functional p53 while the presence of non-bipolar spindles 
hints to mitotic catastrophe as the process which is induced (de Bruin & Medema, 2008). 
 
Figure 6.1: Abnormal spindle formation in apoptin-expressing Saos-2 or U2Os osteosarcoma cells. Cells were 
transiently transfected with plasmid encoding flag-apoptin or flag- SPRR4 and fixed 72 h or 48 h post 
transfection (Saos-2 and U2Os respectively). Flag-tagged apoptin or flag-tagged SPRR4 were stained with a 
flag-specific antibody conjugated to rhodamine (red), endogenous tubulin with a FITC-labeled tubulin-specific 
antibody (green) and DNA with Hoechst (blue). Both transfected and non-transfected cells (in the same dish) 
were analyzed for spindle formation. Bipolar spindles were scored as normal, all others as abnormal. Data 
obtained from Saos2 cells are represented in panels A-G and those from U2Os cells in panels H-N. Panels A 
and H represent the percentages of abnormal spindle formation from 3 separate experiments for each cell line 
(represented as mean ± SD). Per experiment 100 mitotic cells which were positive or negative for flag-apoptin 
or flag-SPRR4 were scored. Apoptin-positive mitotic cells contained significantly more abnormal spindles 
(p<0.01) than the three control groups (respectively p = 0.004, 0.005 and 0.006 for Saos2 cells and p = 0.002, 
0.008 and 0.005 for U2Os cells).  Representative pictures of normal bipolar spindles in the three control 
groups: (B, I) non-transfected cells in the SPRR4 experiment; (C, J) SPRR4 expressing cells; (D, K) non-
transfected cells in the apoptin experiment. Panels E-G and L-N show representative pictures of abnormal 
spindles in apoptin-positive cells. Scale bar: 5μm. 




Half of the apoptin-positive mitotic cells showed normal spindle formation during 
metaphase in both Saos-2 and U2Os cells (Figure 6.1A and 1H). To examine whether these 
bipolar-spindle-positive cells progressed through mitosis in a regular fashion, dividing cells 
were scored according to their respective phases in mitosis: prophase, metaphase, anaphase, 
or telophase. Non-transfected cells displayed all four mitotic phases (Figure 6.2A). Regular 
mitotic figures in apoptin-positive cells were, however, mainly restricted to prophase (Figure 
6.2B) and metaphase (Figure 6.2C), while in SPRR4-transfected control cells anaphase 
(Figure 6.2D) and telophase (Figure 6.2E) cells could readily be found. For quantification 
purposes mitotic cells were classified in groups of prophase/metaphase or 
anaphase/telophase. In Saos-2 cells apoptin expression resulted in a six fold drop in 
anaphase/telophase cells (Figure 6.2F). In U2Os cells apoptin induced a three times decrease 
in anaphase/telophase mitotic cells (Figure 6.2G). Apparently, even in those cases where 
spindles appear normal during the metaphase in apoptin-expressing cells, cells are not able to 
easily progress past the spindle assembly checkpoint into anaphase. 
During our analysis apoptotic cells were observed in which tubulin staining indicated 
that apoptin-induced cell death had occurred during the mitotic cell cycle stage. These 
include late apoptotic cells with clear spindle remnants (Figure 6.2H), an apoptin-positive 
mitotic cell with three spindles that has undergone apoptosis during telophase (Figure 6.2I) 
and finally  an apoptin-positive cell that during earlier steps in mitosis would have been 
classified as normal, but now shows apoptotic blebbing and DNA fragmentation during 
cytokinesis (Figure 6.2J). 
In order to firmly establish that mitosis is disturbed (at various stages) in apoptin-
positive cells we performed live-cell-imaging by using fluorescent time-lapse 
videomicroscopy (Rello-Varona et al., 2010) of U2Os (Figure 6.3A/B/C) or Saos-2 cells 
(Figure 6.3D) transiently transfected with plasmid encoding mCherry-tagged apoptin (red 
fluorescence) and GFP-tagged tubulin (green fluorescence). Cells that were only positive for 
GFP-tubulin divided with similar kinetics as untransfected cells, in approximately 1 hour 
(Figure 6.3A). An apoptin-expressing cell with three spindles eventually generates daughter 
cells undergoing apoptosis during cytokinesis (Figure 6.3B). Note that the different phases 
are prolonged as compared to the cells only expressing GFP-tubulin (compare panel A with 
panel B). For example prophase lasts 4.5 hours in the apoptin-positive cell compared to 12 





apoptin-positive cell starts to undergo regular mitosis with the formation of two 
centrosomes and two spindles (Figure 6.3C). Notice that prophase is delayed to such an 
extent that an untransfected cell (white circle) completes an entire round of mitosis during 
the same time. Division is halted during metaphase and after a block of several hours the cell  
 
Figure 2 Apoptin inhibits mitotic cells from progressing through anaphase and telophase. U2Os and Saos-2 
cells were transiently transfected with plasmid encoding flag-SPRR4 or flag-apoptin and processed for 
immune fluorescence analysis as described in the legend of figure 1. Both flag-apoptin transfected and 
untransfected mitotic cells were scored according to their phase in mitosis. Representative images of the four 
phases in U2Os are in (A) from left to right prophase, metaphase, anaphase and telophase. Apoptin-positive 
mitotic U2Os cells could be found in prophase (B) and metaphase (C), but were scarce in anaphase and 
telophase, whereas SPRR4-positive mitotic U2Os cells were readily found in anaphase (D) and 
telophase/cytokinesis (E). Apoptin transfected mitotic cells were scored as described above, grouped as 
prophase/metaphase and anaphase/telophase and compared to untransfected cells in the same experiment. 
The results from 3 separate experiments (represented as means ± SD) in which 100 mitotic cells per group 
were counted are given. Panel F: Saos-2 cells (** p= 0.0041). Panel G: U2Os cells (** p= 0.0055). Scale bar: 
5μm. Panels H-J: Apoptin-positive cells are shown that undergo apoptosis during mitosis: (H) after spindle 
formation, (I) during abnormal cytokinesis and (J) during normal cytokinesis. Scale bar: 10μm. 




becomes apoptotic. Under similar conditions a Saos-2 cell undergoes a round of seemingly 
normal mitosis, i.e. the cell generates two daughter cells. However, phases are prolonged and 
in the interphase following division both daughter cells undergo cell death (Figure 6.3D). 
Our analysis proves that in apoptin-expressing tumor cells various well defined 
events occur in a clearly successive manner. These include perturbed spindle formation, 
slower progression through the various phases of mitosis and eventually induction of cell 
death. Therefore, the observed behavior of a mitotic cancer cell expressing apoptin 
conforms to the set of characteristics attributed to mitotic catastrophe by the 2012 
Nomenclature Committee on Cell Death: a) it is triggered by perturbations of the mitotic 
apparatus; b) it is initiated during the M phase of the cell cycle; c) it is paralleled by some 
degree of mitotic arrest; d) it ultimately triggers cell death or senescence (Galluzzi et al., 
2012).  
We have recently shown that apoptin can be activated in normal cells by inactivation 
of the B56γ or δ subunits of PP2A (Zimmerman et al., 2012). The PP2A-B56 complex is 
essential for the stabilization of kinetochore-microtubule attachments and plays an important 
role in correct chromosome segregation (Foley et al., 2011). Similarly, knockdown of the 
spindle assembly checkpoint (SAC) kinase Bub1 can trigger tumor-like behavior of apoptin 
in normal cells (Kucharski et al., 2011). Apparently apoptin can sense malfunctioning of the 
SAC. In the present study, both the timing of initiation (at the meta-to-anaphase transition) 
and the character of the various mitotic perturbations that are observed also pinpoint at an 
activation of apoptin around the mitotic spindle checkpoint. As many (if not all) human 
tumor cells have a weakened SAC (Kops et al., 2005) our analysis implies that apoptin is 
likely able to sense minor inaccuracies of the SAC in tumor cells in a similar way as 
previously shown in genetically modified normal cells (Zimmerman et al., 2012; Kucharski et 
al., 2011). 
How then can active apoptin induce mitotic instability and cell death? As long as 
spindles are not correctly organized and not all kinetochores are properly attached, the SAC 
is activated and prevents progression through mitosis by directly signaling to the anaphase-
promoting complex/cyclosome (APC/C) (Musacchio and Salmon, 2007). Inhibition of 
APC/C by the SAC leads to stabilization of cyclin B1 and prolonged activation of cyclin B1 
is associated with mitotic catastrophe (Chan et al., 2009). In this respect it is relevant to 












Figure 6.3: Dividing apoptin-positive osteosarcoma cells undergo mitotic catastrophe resulting in apoptosis. 
U2Os and Saos-2 cells were transiently transfected with plasmids encoding GFP-tubulin (green) and mCherry-
apoptin (red) and analyzed by time-lapse microscopy. Cells were incubated with Hoechst 33342 DNA stain 
(blue) prior to picture capturing. Time-lapse images for blue (DNA), green (tubulin) and red (apoptin) signal 
were recorded for 20 h every 2 min, for U2Os cells from 40 h – 60 h post transfection and Saos-2 cells from 
65 h – 85 h post transfection. Time points of recording are indicated next to the respective images. Filmstrip 
(A) displays several U2Os cells transfected solely with GFP-tubulin and dividing normally (1 h to complete 
mitosis). One dividing cell is encircled with a white ring. Strip (B): mCherry-apoptin-positive U2Os cell with 
abnormal spindle formation completing mitosis but undergoes apoptosis during telophase after progression 
through mitosis has been seriously delayed. (C) mCherry-apoptin-positive U2Os cell with normal spindle 
formation arrested during metaphase and eventually undergoing apoptosis during the same phase. An 
untransfected cell completes mitosis with normal kinetics in the same culture (white ring). In strip (D) an 
mCherry-apoptin-positive Saos-2 cell undergoes seemingly normal but prolonged mitosis and apoptotic cell 
death occurs after cytokinesis in the two daughter cells. Scale bar: 20μm. 
 
expression in cancer cells (Teodoro et al., 2004). Additionally it has been shown that apoptin 
is able to associate directly with APC1, a subunit of the APC/C, and that the resulting 
inactivation of APC/C is sufficient for the induction of apoptosis (Teodoro et al., 2004). 
By combining the cellular analysis, which is presented here, with the earlier molecular 
evidence mentioned above, the following model of apoptin action arises. Apoptin senses a 
weakened SAC (Zimmerman et al., 2012; Kucharski et al., 2011) and binds directly to APC1 
which is dislodged from the APC/C complex (Teodoro et al., 2004). Inhibition of APC/C 
results in a serious disabling of the mitotic checkpoint control, resulting in blockage of the 
meta-to-anaphase transition (Figure 6.2F/G) and the appearance of atypical non-bipolar 
spindles (Figure 6.1). Cell death can be induced either in cells arrested before transition to 
anaphase, during the progression to cytokinesis or even in daughter cells arising by 
inaccurate cell division (Figure 6.2H/I/J). The various disturbances of the mitotic process 
have been recorded by live-imaging and represented as filmstrips (Figure 6.3A/B/C/D). 
Weak inaccuracies in mitotic checkpoints are believed to be responsible for 
aneuploidy and genetic instability (Kops et al., 2005), which are inherent to cancer cells and 
drive tumor progression (Hanahan & Weinberg, 2011). Apparently, apoptin is able to sense 
these inaccuracies during cell division and disrupts a cancerous process by triggering mitotic 









Matherials & Methods 
Cell culture 
The human osteosarcoma cell lines Saos-2 (p53-null) and U2Os (p53 wild type) were 
purchased from the American Type Culture Collection (ATCC, Wesel, Germany) and 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (PAA, Diegem, Netherlands) 
containing 10% newborn calf serum (Thermo Scientific, Geel, Belgium), 100μg/mL 
penicillin, 100μg/mL streptomycin  (Duchefa, Biochemie, Haarlem, The Netherlands) and 
2mM glutaMAX (PAA). Cells were cultured at 37°C in a humidified 5% CO2 incubator. Cell 
morphology was regularly monitored to control the absence of cross-contamination. 
 
Plasmids 
The construction and expression of pcDNA3.1(+)flag-apoptin was previously described 
(Zimmerman et al., 2012) and contains the apoptin sequence published by Noteborn and co-
workers (1991) fused with a flag-tag (Life Technologies, Bleiswijk, Netherlands) at its N-
terminus. Full-length SPRR4 cloned into the pECV25 expression vector was previously 
described (Vermeij et al., 2011) and provided with the same N-terminal flag-tag as apoptin. 
SPRR4 was chosen as a control because, in contrast to apoptin, it does not induce apoptosis 
(supplementary Figure S6.1A) but still shares many biochemical characteristics with apoptin, 
i.e. protein size, high proline content, isoelectric point, nuclear/cytoplasmic localization 
(supplementary Figure S6.1B-E) and DNA binding (Leliveld et al., 2003a; Vermeij et al., 
2012). Plasmid encoding GFP-tubulin was purchased from Clontech (Mountain View, CA). 
mCherry was amplified by PCR from pRSET-b-mCherry (Shaner et al., 2004) and 
introduced into pcDNA3.1(+)apoptin to yield a plasmid encoding apoptin N-terminally 
fused to mCherry. 
 
Transfections 
Cells were transfected with plasmids by using Amaxa nucleofection (Lonza AG, Cologne, 
Germany) according to an adaptation of the manufacturer’s protocol. Briefly, 106 cells were 
taken up in 120μL nucleofector buffer (90mM Na2HPO4/NaH2PO4 pH 7.2, 5mM KCl, 
10mM MgCl2, 20mM Hepes), mixed with DNA, transferred to a transfection cuvet (VWR, 
Amsterdam, The Netherlands) and transfected with program D-24 or X-01 for Saos-2 or 




U2Os, respectively. After addition of medium, cells were either seeded on glass cover slips 
or in dishes appropriate for time-lapse microscopy. 
 
Immune fluorescence assay 
Cells grown on glass cover slips were, at indicated time points after transfection, first washed 
with phosphate buffered saline (PBS), and subsequently fixed for 10 min with 1% 
formaldehyde, 5 min with 100% methanol and 2 min with 80% acetone, all at room 
temperature. After air-drying the slides were used for immunocytochemical staining or 
stored at -20°C for further analysis. For the antibody staining, the cells were first incubated 
with PBS, 0.05% Tween 20 (PBS-Tween) (Sigma Aldrich, Zwijndrecht, Netherlands), 5% 
normal goat serum (NGS) (Sigma Aldrich) for 1 h. Next, the cells were incubated with the 
first antibody in the same buffer for 2 h, washed with PBS-Tween, and incubated with the 
second antibody in PBS-Tween, 5% NGS for 1 h. After washing with PBS-Tween cells were 
incubated 15 min with Hoechst 33358 (2μg/mL). Stained sections were mounted using 
PolyMount Mounting Media (Tebu-Bio, Heerhugowaard, Netherlands) and analyzed with a 
fluorescence microscope (Olympus, Zoeterwoude, The Netherlands) with the Cell P 
software version 2.8 (Olympus). The following antibodies were used: anti-flag (rabbit 
polyclonal, 1:150, Sigma Aldrich) together with a rhodamine-conjugated goat antibody (1:100, 
Sanbio, Uden, The Netherlands), and monoclonal mouse-anti-tubulin conjugated with 
fluorescein isothiocyanate (FITC) (1:100, Sigma Aldrich). Mitotic cells were scored based on 
their tubulin and DNA staining. Apoptosis was assessed based on characteristic DNA 
staining (Danen-van Oorschot et al., 1997). 
 
Live-cell imaging 
Transfected cells were incubated with 6.25 or 25 ng/mL Hoechst 33342 for Saos-2 or U2Os 
respectively at the indicated time points after transfection. Live cell imaging was performed 
on an Olympus IX81 time-lapse microscope equipped with an MT10 lamp (Olympus) and 
different excitation and emission filters (Olympus). Images were captured every 2 min for 20 
h with the appropriate settings for GFP, mCherry and Hoechst. Movies were analyzed with 
the Cell M software version 3.1 (Olympus). Results are represented as filmstrips (Figure 6.3) 







Each immune fluorescence assay was performed 3 times. For each experiment 100 mitotic 
cells were scored per group. Datasets were analyzed with the paired two-tailed student’s t-
test in which apoptin positive mitotic cells were compared to each of three negative control 
groups. All data are means ± standard deviation (SD); p values below 0.05 were considered 
significant (** p<0.01). 
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Supplementary Figure S6.1: Apoptin but not SPRR4 induces apoptosis in osteosarcoma cell lines. Saos-2 and 
U2Os cells were transfected with plasmid encoding flag-apoptin or flag-SPRR4 (control) and were fixed 72 h 
or 48 h post transfection (Saos-2 and U2Os respectively). The percentage of apoptosis (represented as means 
± standard deviation) induced by apoptin and SPRR4 in Saos-2 and U2Os cells was scored by aberrant DNA 
staining30. SPRR4 did not induce apoptosis in these cells compared to apoptin (A). Flag-tagged apoptin or 
flag-tagged SPRR4 were stained with a flag-specific antibody conjugated to rhodamine (red), endogenous 
tubulin with a FITC-labeled tubulin-specific antibody (green) and DNA with Hoechst (blue). Apoptin 
localizes to the nucleus of interphase cells (panels B, D) and SPRR4 to both nucleus and cytoplasm (panels C, 








Summary & Discussion 
 
Proteins Killing Tumor Cells: 
 











Hallmarks of cancer 
In 2000, Hanahan and Weinberg revolutionized the way the scientific world thought about 
cancer. By describing the hallmarks of cancer, they set a framework to discuss and think 
about the specific contours of tumorigenesis. Though each cancer is different on the 
molecular level, the same set of alterations is often needed for a cancer cell to become a full 
blown neoplasia. These alterations are described by eight hallmarks of cancer and two 
enabling characteristics (Hanahan & Weinberg, 2000; 2011) (see also chapter two).  
The hallmarks can be roughly grouped as endogenous and exogenous. Endogenous 
being those traits that regulate tumorigenesis inside a cell (sustaining proliferative signaling, evading 
growth suppressors, enabling replicative immortality and resisting cell death) and exogenous those that 
induce changes in the cell’s environment to further support the development of the tumor 
(inducing angiogenesis, activating invasion & metastasis, deregulating cellular energetics and avoiding immune 
destruction). While the hallmarks are the traits acquired by a transformed cell, the enabling 
characteristics are those features that allow the acquisition of the changes that constitute the 
hallmarks.  
 
Proteins killing tumor cells 
Proteins Killing Tumor Cells (PKTCs) are a group of proteins all shown to have selective 
cell death inducing activity against tumor cells, having no detrimental effect on healthy tissue. 
This in contrast to regular anti-cancer drugs, which have many unwanted side effects. The 
eleven currently known PKTCs have been described in detail in chapter two. In short there 
are various classes: the virus-derived apoptin, E4orf4 and NS1; frog-derived Brevinin-2R and 
onconase; HAMLET is created in vitro from human breast milk; finally there are the human 
proteins that under the right conditions can help to battle cancer, TRAIL, noxa, mda-7/IL-
24, Par-4 and ORCTL3. All PKTCs tested in (pre)clinical trials show positive outcomes.  
As with the hallmarks of cancer, all PKTCs have a common trait, the selective killing 
of cancer cells, but it is caused by different triggers on a molecular level. The upstream 
activating characteristics of a cancer cell that activate a PKTC might differ per protein, and 
the downstream execution of cell death activation is also variable. Here we set out to test the 
hypothesis that the selectivity of PKTCs is achieved through the recognition of the 






Tumor-related derailment of protein phosphatase 2A activates apoptin 
Apoptin behaves differently in normal cells as compared to tumor cells. Not only does it 
induce apoptosis in cancer cells, it translocates to the nucleus and becomes phosphorylated. 
These features made it possible to monitor the switch during tumorigenesis that constitutes 
for apoptin the change from a normal to a tumor cell. In chapter three, we examined 
whether inactivation of two specific B56 subunits of protein phosphatase 2A (PP2A) is 
sufficient to activate the tumor-selective behavior of apoptin in normal cells. The simian 
virus 40 antigens large T and small T (SV40 LT and ST) has previously been shown to be 
oncogenic to normal cells and could activate apoptin (Zhang et al., 2004). Here, we found 
that cancer-selective activation of apoptin occurs through inactivation of the PP2A-B56γ 
complex. In addition the observed interaction of apoptin with BCA3/AKIP1 led to a series 
of experiments to manipulate protein kinase A (PKA). Indeed, BCA3/AKIP1 is an inhibitor 
of this tumor-related kinase and stimulation of PKA blocked apoptin activation, whereas 
inhibition of PKA had the opposite effect. Importantly, activation of apoptin could be 
achieved through inactivation of the PP2A-B56δ complex.  
Inactivation of PP2A complexes is a known step in tumorigenesis (Westermarck & 
Hahn, 2008), and one that is apparently recognized by apoptin. Interestingly, both B56δ and 
B56γ are nuclear B56 subunits and PP2A-B56 complexes were shown to be involved in the 
formation of stable attachments between kinetochores and microtubules. Correct attachment 
deactivates the spindle attachment checkpoint and allows progression through mitosis (Foley 
et al., 2011). As will be discussed below, apoptin likely senses deregulations during mitosis, 
which are caused by the disruption of correct spindle attachments due to disturbed PP2A-
B56 complex formation. 
E4orf4 does not detect irregularities in PP2A complexes, but causes them. By 
binding to PP2A-B55 E4orf4 lowers the activity of the PP2A complex resulting in 
hyperphosphorylation (Li et al., 2009b). E4orf4 interaction with PP2A-B55 leads to G2/M 
arrest and cell death, possibly through changing the balance in chromatin remodeling 
complexes. PP2A leads E4orf4 to the ACF-SNF2h complex and by inhibiting ACF, liberates 
SNF2h to form other complexes. This switch in chromatin remodeling supports the 
induction of cell death (Brestovitsky et al., 2011). Interestingly apoptin interacts with another 
factor that can form a chromatin remodeling complex with SNF2h, namely Rsf1 (remodeling 




and spacing factor 1) (Danen-van Oorschot, unpublished data). Rsf1 is over-expressed in an 
increasing number of cancer types and levels are correlated to disease aggressiveness (Li et al., 
2012). Over-expression of Rsf1 in normal cells leads to DNA damage signaling and 
promotes genomic instability (Sheu et al., 2010). DNA damage signaling activates apoptin in 
normal cells (Kucharski et al., 2011). High levels of Rsf1 in cancer cells potentially facilitate 
apoptin both in an upstream activating and downstream executive fashion. The DNA 
damage signaling by Rsf1 could activate apoptin, and by direct binding to Rsf1 apoptin could 
disrupt the abnormal high levels of Rsf1-SNF2h complex, releasing SNF2h for other 
complexes in a similar fashion as E4orf4.   
 
Proteasomal degradation 
A novel distinguishing feature of apoptin which differs between normal and tumor cells was 
discovered in chapter four. Normal cells efficiently shield apoptin (Zhang et al., 2004) and 
degrade the protein through the proteasomal degradation pathway. In cancer cells, this 
clearance does not seem to be functional (Lanz et al., 2012b, chapter four). This differential 
characteristic contributes to apoptin safety in cancer treatment. The precise processes 
responsible for the differential apoptin stability is unclear: no differences in proteasome 
composition between normal and tumor cells have yet been reported, however, changes in 
proteasome subunit modifications can cause differential degradation by nuclear and 
cytoplasmic proteasomes (Guo et al., 2011). The differential localization and degradation of 
apoptin could be related. Per analogy, the nuclear localization and stability of the serine 
hydroxymethyltransferase 1 (SHMT1) is determined by competition between sumoylation 
and ubiquitination of the protein (Anderson et al., 2012). Apoptin can be sumoylated in 
tumor cells (Janssen et al., 2007), which might explain of its insensitivity to proteasomal 
degradation in tumor cells.  
 Unfolded proteins are degraded by the proteasome. HAMLET, a partially unfolded 
PKTC, is indeed targeted to the proteasome, but resists degradation and influences 
proteasomal activity (Gustafsson et al., 2009). Possibly the inhibition of the proteasome leads 
to changes in protein levels and shifts in the Bcl-2 family the balance in favor of the pro-
apoptotic members, leading to cell death (Adams & Cory, 2007). Apoptin has not been 
shown to disturb proteasome activity directly, however, by interacting with a subunit from 





an E3 ligase (Teodoro et al., 2004). The APC/C is the major E3 ligase in the nucleus 
responsible for the correct timing of degradation of cell cycle regulatory proteins (Garcia-
Higuera et al., 2008). Furthermore, apoptin can induce the expression of the E3 ligase PIR2, 
leading to a shift in the balance between pro-survival ΔNp73 and pro-death TAp73 in favor 
of the latter (Taebunpakul et al., 2012). 
Misfolded proteins in the endoplasmic reticulum (ER) activate the Unfolded Protein 
Response (UPR). Normally unfolded proteins from the ER are degraded by the ubiquitin-
proteasome pathway (Liu & Ye, 2011). Upon activation of the UPR several processes are 
activated that block translation, activate macroautophagy and change transcription. A cell 
can sense the duration of the UPR, when the ER stress caused by unfolded proteins persists 
for too long, cell death processes are activated. Under normal conditions two of the UPR 
effectors, IRE1α and PERK, are inactive due to binding to GRP78/BiP. During ER stress, 
GRP78/BiP binds to unfolded proteins, releasing IRE1α and PERK (Hetz, 2012). 
GRP78/BiP is over-expressed in cancer cells which helps to suppress cell death pathways 
(Sato et al., 2010). It is a popular target among PKTCs as Par-4, Mda-7/IL-24 and apoptin 
can interact with GRP78/BiP (Burikhanov et al., 2009; Gupta et al., 2006; Danen-van 
Oorschot, unpublished results), presumably by activation of the UPR and subsequent cell 
death induction. 
 
Tumor-selective phosphorylation of apoptin 
It has been proposed that the nuclear localization of apoptin depends on its tumor-selective 
phosphorylation of threonine 108 (Poon et al., 2005). The identity of the kinase responsible 
for apoptin phosphorylation is still under debate, with both cyclin dependent kinase 2 
(CDK2) and protein kinase c isoform β (PKCβ) coined for the job (Maddika et al., 2009; 
Jiang et al., 2010). In chapter five, we showed that neither one of them is required in our in-
vitro phosphorylation assay of apoptin (Lanz et al., 2012a). It was also shown that T107 can 
be phosphorylated, with T108 present. Previously, it was shown that upon mutation of T108 
apoptin can still induce apoptosis (Rohn et al., 2005). It could be possible that the T108 of 
apoptin falls within the consensus sequence of more than one kinase. The Herpes simplex 
virus 1 protein Us3 can be phosphorylated on serine 147 both by itself and by PKA which 
influences its localization and activity (Kato et al., 2008). Other PKTCs such as E4orf4 or 




NS1 also interact with specific kinase activities such as Src tyrosine kinases and casein kinase 
II, respectively, enabling their activation (Noteborn, 2009a).  
 
Genomic instability and mitotic catastrophe 
More than one hundred years ago, the German scientist Theodor Boveri observed that the 
equal distribution of duplicated chromosomes among daughter cells is crucial for embryonic 
development (Holland & Cleveland, 2009). Many cancers have an incorrect number of 
chromosomes, a situation termed aneuploidy. Furthermore, a lot of tumors vary in their 
number of chromosomes due to loss or gain during mitosis, a concept named chromosomal 
instability (Kops et al., 2005). Genomic instability is propagated during mitosis. Incorrect 
spindle assembly and chromosome segregation lead to unequal distribution. The mitotic 
checkpoint, or spindle assembly checkpoint (SAC) should arrest cells during mitosis as long 
as chromosomes are not correctly attached. Many tumor cells have a weakened SAC due to 
mutations or altered protein levels of components of the checkpoint (Kops et al., 2005). An 
important target in the mitotic checkpoint is the APC/C. Inhibition of the APC/C by the 
SAC blocks mitosis in the meta-to-anaphase transition. Apoptin can bind the APC1 subunit 
of the APC/C and block cell cycle progression (Teodoro et al., 2004; chapter six). E4orf4 
blocks cell cycle progression also through manipulation of the APC/C (Smolders and 
Teodoro, 2011).  
In healthy cells, one unattached kinetochore is enough to activate the SAC. In tumor 
cells more dramatic deviations need to occur to block mitosis (Kops et al., 2005). We infer 
that apoptin senses mitotic abnormalities, for example caused by deregulated PP2A 
complexes or a weakened SAC. In chapter six, we showed that apoptin causes apoptosis 
through the induction of mitotic catastrophe. In an already chromosomal instable cancer cell 
background apoptin causes an even bigger mitotic mayhem pushing the tumor towards cell 
death. Apoptin might sense mitotic inaccuracies through its interaction with Fam96B 
(Zimmerman et al., 2011). Fam96B is part of a complex that is essential for proper 
chromosome segregation (Ito et al., 2010). An extra level of DNA inaccuracy sensing is likely 
done by apoptin through its interaction with DEDAF (Danen-van Oorschot et al., 2004). 
Furthermore, disruption of chromatin, and increased signaling to the SAC, might be 
mediated by apoptin through its interaction with Rsf1 as described above. Together with its 





manages to activate a weakened SAC by increasing upstream signaling. E4orf4 over-
expression in human lung cancer H1299 cells revealed the occurrence of tetraploid and 
polyploid cells and the appearance of micronuclei, suggesting that E4orf4 induces mitotic 
catastrophe which eventually leads to cell death (Li et al., 2009a).  
 
Cancer, Hallmarks and PKTCs 
A lot of effort in the field of PKTCs is invested in showing the clinical importance and use 
of the protein in (pre)clinical testing. Alongside there is a lot of investigation into the 
downstream pathways of PKTCs involved in inducing the cell death, and how this relates to 
the tumor-selectivity. Our literature review revealed that only rarely investigations are 
undertaken to specifically identify which tumorigenic changes are needed in a cell in order to 
activate a PKTC, as for example the SV40 research in the case of apoptin (Zhang et al., 2004; 
Zimmerman et al., 2012) and the knock down of oncogenic pathways related to HAMLET 
functionality (Storm et al., 2011). Upstream activating hallmarks are important as they will 
help identify which cancer types will be susceptible for treatment with a specific PKTC, 
leading to personalized medicine. In this chapter we have used the cellular components that 
are recognized by PKTCs (Table 7.1) and are responsible for their selective cell death 
induction, to link PKTCs to their upstream activating hallmarks of cancer (Table 7.2).  
There is a huge diversity in how strictly or broadly a hallmark is described. Some are 
very well defined, with clear cellular markers. For example, enabling replicative immortality is 
a hallmark with very clearly defined markers. In most cancers this is achieved by re-activating 
telomerase, and in some situations by alternative lengthening of telomeres. On the other 
hand, the sustainment of proliferative signaling can be achieved by modulating one of many 
cellular pathways. Sometimes it is not so much the hallmark that is recognized by the PKTC 
as much as the oncogene causing a hallmark(s), e.g. oncogenic RAS-activation of TRAIL 
(Nesterov et al., 2004). As shown in table 7.1, eight out of ten cancer hallmarks/enabling 
characteristics are detected by one or more of the different PKTCs.  
The first two hallmarks involved in keeping up unscheduled growth are recognized 
by many of the PKTCs. Both the sustainment of proliferative signaling and evasion of 
growth suppressors are broadly defined hallmarks, with many of the major signaling 
pathways involved. They are essential already early in tumorigenesis (Hanahan & Weinberg, 
2000). Because these two hallmarks are caused by mutations in crucial components of 




important pathways, e.g. oncogenic c-Myc (Whitfield & Soucek, 2012), they are linked to 
other hallmarks as well. In case of some PKTCs it is not always clear if there is a direct 
relationship between the marker of the hallmark and activation of the PKTC, or if it is a 
downstream effect within one specific hallmark. 
The resistance of cell death signaling is a hallmark that can activate six PKTCs 
(apoptin, NS1, TRAIL, Noxa, mda-7 and Par-4). GRP78/BiP is a key component in PKTC 
recognition of cell death resistance though the effect is different depending on the PKTC. 
GRP78/BiP is a chaperone that normally resides in the ER. Upon ER stress it locates to the 
cellular membrane. In cancer cells it is over-expressed on the cell surface (Sato et al., 2010). 
For instance, Mda-7/IL-24 inactivates GRP78/BiP in the ER triggering the Unfolded 
Protein Response (Dash et al., 2010a). In contrast, Par-4 activates the cellular membrane 
bound GRP78/IL-24 leading to caspase activation (Burikhanov et al., 2009). Either way, it  
is the abnormal amount of GRP78/BiP that is characteristic for tumor cells, that upon 
further deregulation by a PKTC leads to cell death. 
Some hallmarks as the deregulation of cellular energetics and the avoidance of 
immune destruction seem to be less recognized by PKTCs. However, this might be due to a 
lack of active research in these areas on PKTC activation. In case of HAMLET is does play 
an important role (Storm et al., 2011) and it might be informative about the other PKTCs as 
well. So far there are no reports on the influence of oxidative glycolysis on PKTC activation.  
Several crucial oncogenes as Src, c-Myc and RAS (Table 7.1 and references within) 
link PKTCs to angiogenesis induction. As these oncogenes are involved in the occurance of 
several hallmarks it is not always clear whether the PKTC recognizes angiogenesis per se.  
Parvoviruses, encoding NS1, optimally use the evasion of the immune system by 
cancer cells to their advantage (Rommelaere et al., 2010). As discussed above, apoptin and 
E4orf4 might sense irregularities during mitosis, and this genomic unstable background 
could be one of the triggers for them to induce mitotic catastrophe. 
Replicative immortality seems to be a hallmark that none of the PKTCs use to their 
advantage. Even worse, the re-activation of telomerase, one of the main molecular 
characteristics of this hallmark, actually negatively influences some of the PKTCs, Par-4 and 
TRAIL (Sheng et al., 2010; Zhang et al., 2010). In contrast, several therapy-focused 
experiments with PKTCs use vectors on which the gene of interest is expressed downstream 





the gene (apoptin: Li et al., 2010 and TRAIL: Li et al., 2011a). In this fashion, recognition of 
this hallmark of cancer can be indirectly added to the spectrum of PKTCs. 
The emerging hallmark of tumor-promoting inflammation also seems to go 
undetected by PKTCs. Not completely surprising as this specific hallmark is completely 
tumor-environment related, and most of the research with PKTCs is done under tissue 
culture conditions. The effect of tumor-promoting inflammation can only be studied in vivo 
and thus far no data on the effect of inflammation on the activation of PKTCs have been 
reported.   
Since the introduction of the concept of ‘hallmarks of cancer’ in 2000 attempts have 
been undertaken to expand and (re)define them, with in 2011 an update by the original 
authors themselves. Luo and colleagues (2009) introduced several cancer-related stresses, to 
further define the concept of a cancer cell. Metabolic, proteotoxic, mitotic, oxidative and 
DNA damage stress are cancer-related, but not all incorporated in the hallmarks of cancer. 
Through their tumor-selectivity PKTCs can point out those aspects of cancer cells 
that set them apart from healthy tissue. They do not so much introduce completely new 
hallmarks as much as point out aspects of hallmarks that thus far went rather unremarked 
and could prove to be important targets in cancer therapy.  
Tumor-selective membrane transport is an import aspect of HAMLET, onconase 
and Brevinin-2R. An important challenge in medication administration is getting the 
compound at the site of action. Tumor-specific uptake of medicines would be a worthwhile 
improvement. Furthermore it points at distinct differences in membrane composition 
between normal and cancer cells. A so called ‘lipogenic switch’, i.e. a change in the lipid 
profile, is reported for many types of cancer (Schug et al., 2012) and could be the reason for 
distinguishable cellular membranes. Apoptin and Mda-7/IL-24 influence ceramide levels, 
potentially exercising an effect on this lipogenic switch (Liu et al., 2006; Dash et al., 2010a). 
Besides regulation at the level of transcription, homeostasis of protein levels is 
mainly achieved by the proteasome. Though several PKTCs influence transcription factors, 
some of them point at an important role for protein degradation in ‘cancer protein 
homeostasis’. Apoptin is degraded in normal, but not in tumor cells by the proteasome 
(Lanz et al., 2012b). HAMLET achieves its own stability and a deregulation of protein levels 
through interaction with the proteasome (Gustaffson et al., 2009). Imbalances in protein 
levels that govern life-or-death decisions potentiate tumor development; PKTC research 




shows that they are not only caused by altered transcription, but also by inaccuracies in 
proteasomal degradation.   
If aneuploidy, or genomic instability in general, is a cause, a consequence, or even a 
cure for tumorigenesis is an ongoing debate (Holland & Cleveland, 2009). However, 
whichever of the three it is, the cellular processes responsible for mitotic instability also 
enable apoptin, and E4orf4, to induce tumor-selective apoptosis. PKTCs indeed sense 
imbalances in crucial cellular processes that are too important to go completely wrong (as 
that would lead to eminent cell death), but when slightly skewed, can pave the way to 
tumorigenesis. Whether it is a weakened SAC that creates genomic instability, or abnormal 
protein levels in the Bcl-2 family, the general theme of PKTC activation seems to be that 
“what allowed a tumor cell to live now leads to its demise”.   
The in-depth study of these proteins, that by one way or another manage to kill 
tumor cells with no harmful side effects, will not only allow us to develop promising cancer 



























apoptin Akt (Maddika et 
al., 2007) PKCβ 
(Jiang et al., 2009) 
PP2A/PKA 
(Zimmerman et al., 
2012) 
PP2A 





Akt (Maddika et 
al., 2007)  PP2A 
(Zimmerman et al., 
2012) 
 
E4orf4     Src (Gingras et al., 
2002) 
NS1 CKII (Nuesch & 
Rommelaere, 2007) 
CKII (Nuesch & 
Rommelaere, 2007)
 CKII (Nuesch & 
Rommelaere, 2007) 
 
onconase      
Brevinin-2R      
HAMLET c-Myc (Storm et 
al., 2011) 
c-Myc (Storm et 
al., 2011) 
  c-Myc (Storm et 
al., 2011) 
TRAIL c-Myc (Kim et 
al., 2011) RAS 
(Nesterov et al., 
2004) 
c-Myc (Kim et 
al., 2011) 
 RAS (Nesterov et 
al., 2004) 
c-Myc (Kim et 
al., 2011) RAS 
(Nesterov et al., 
2004) 
Noxa c-Myc 
(Nikiforov et al., 
2007) 
c-Myc 
(Nikiforov et al., 
2007) 
 Puma (Nakajima 
& Tanaka, 2011) 
c-Myc 
(Nikiforov et al., 
2007) 
mda-7    GRP78/BiP 
(Gupta et al., 2006) 
 
Par-4 PKA 
(Gurumurthy et al., 
2005) 
  GRP78/BiP 
(Burikhanov et al., 
2009) 
 
ORCTL3      
 
Table 7.1: The hallmarks of cancer & enabling characteristics that activate Proteins Killing Tumor Cells.
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(Storm et al., 2011) 
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(Nesterov et al., 
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RAS (Nesterov 
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al., 2002 
PKA Almeida & 
Stratakis, 
2011 
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PKCβ Li et al., 
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RAS Pylayeva-
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Kanker is een verstoring van de balans tussen het delen en het natuurlijk afsterven van cellen. 
De transformatie van een gezonde naar een kankercel is een meervoudig proces. 
Transformatie bestaat uit een opeenstapeling van kleine verstoringen in belangrijke cellulaire 
processen. Voor elke kanker is het pakket aan verstoringen uniek, alleen het resultaat lijkt 
gelijk. In 2000 zijn de zogenaamde ‘hallmarks of cancer’ geïntroduceerd. Deze benoemen de 
specifieke veranderingen die altijd nodig zijn voor de formatie van een kankercel, 
onwillekeurig hoe deze zich op moleculair niveau hebben voltrokken. Hoofdstuk 2 begint 
met de omschrijving van de huidige ‘hallmarks of cancer’, waaronder het ontduiken van 
geprogrammeerde celdood en het immuunsysteem, activering van eindeloos delen en het in 
staat stellen tot uitzaaiingen. 
Een groot struikelblok bij de behandeling van kanker is het gebrek aan selectiviteit 
binnen de huidige medicatie. Medicijnen die ingrijpen in bepaalde ontregelde processen 
beïnvloeden ook processen in gezonde cellen. In hoofdstuk 2 wordt een groep eiwitten 
geïntroduceerd genaamd ‘Proteins Killing Tumor Cells’ (PKTCs, eiwitten die kankercellen 
vermoorden). Expressie van deze eiwitten leidt selectief in tumorcellen tot de inductie van 
gecontroleerde celdood (apoptose), terwijl normale cellen ongemoeid worden gelaten.  
Het doel van dit proefschrift is het ontrafelen van de gedereguleerde cellulaire 
processen die worden herkend door apoptin, de eerste van de PKTCs. Deze processen 
differentiëren tussen normale en tumorcellen en vormen een aangrijppunt voor nieuwe 
therapieën.  
Apoptin is een klein eiwit dat wordt gemaakt door een kippenvirus, Chicken Anemia 
Virus (CAV). Voor kuikens is in het veld besmetting met dit virus, veelal in combinatie met 
het transformerende Marek’s disease virus, dodelijk doordat het apoptose induceert in de 
thymus (zwezerik). Verantwoordelijk voor de dood van in-vitro getransformeerde Marek’s 
disease virus cellen bleek het derde eiwit van CAV te zijn, apoptin. Apoptin bleek selectief 
celdood te induceren in menselijke kankercellen. CAV is niet besmettelijk voor mensen. 
Experimenteel kan het apoptin-eiwit wel tot expressie worden gebracht in menselijke cellen 
m.b.v. plasmiden, en geproduceerd apoptin-eiwit kan in cellen worden geïntroduceerd. 
 Apoptin heeft een aantal karakteristieken die verschillend zijn tussen normale en 
tumorcellen. Meest kenmerkend is dat apoptin onschadelijk is voor normale cellen, maar 





terwijl in getransformeerde cellen het apoptin-eiwit zich verplaatst naar de kern van de cel. 
Wanneer apoptin met een bepaalde techniek tijdelijk tot expressie wordt gebracht in humane 
cellen valt het op dat het eiwit snel niet meer te detecteren is in normale cellen, terwijl het in 
tumorcellen lang stabiel blijft. In hoofdstuk 4 laten wij zien dat dit komt omdat in 
kankercellen het apoptin-eiwit niet langer wordt afgebroken door het proteasoom.  
Verschillende cellulaire situaties vragen om verschillende eiwitcomposities in de cel. 
Om hier flexibel mee om te gaan worden er continu bepaalde eiwitten aangemaakt, en ook 
weer afgebroken. Beide processen worden strikt gereguleerd. Alleen eiwitten gelabeld voor 
destructie worden ‘uit het veld’ genomen. Het proteasoom is een eiwitcomplex dat gelabelde 
eiwitten herkent en afbreekt tot kleinere, herbruikbare moleculen. Wanneer wij in normale 
cellen de werking van het proteasoom blokkeren met verschillende chemische verbindingen 
blijft de hoeveelheid apoptin stabiel. Dit impliceert dat het apoptin-eiwit normaal gesproken 
wordt afgebroken door het proteasoom. In tumorcellen heeft het blokkeren van de afbraak 
van eiwitten geen effect op de hoeveelheid apoptin. Dit is gunstig voor de ontwikkeling van 
apoptin als medicijn. Belangrijk bij de ontwikkeling van medicatie is dat deze ook weer 
verwijderd kan worden uit het lichaam. Doordat apoptin van nature instabiel is in normale 
cellen, en stabiel in tumoren, wordt zijn selectieve effect vergroot. Daarnaast duidt dit 
verschil in afbraak van apoptin op een algemene verstoring in de regulatie van eiwitniveaus 
in kankercellen.  
 Een andere methode die een cel tot zijn beschikking heeft om snel op veranderende 
situaties te reageren, is door eiwitten aan en uit te schakelen in plaats van te maken en af te 
breken. Het (de)activeren van eiwitten gebeurt voornamelijk door het koppelen van een 
fosfaatgroep aan een eiwit, fosforyleren. Apoptin wordt selectief in tumorcellen 
gefosforyleerd op Threonines 107 en 108 (hoofdstuk 5). De negatieve lading van een 
fosfaatgroep leidt vaak tot een structuurverandering die bijvoorbeeld een katalytisch deel van 
het eiwit blokkeert. In het geval van apoptin resulteert de fosforylering in kankercellen tot 
blokkering van het signaal voor transport de kern uit, en uiteindelijk tot het verschil in 
cellulaire lokalisatie.  
Fosforylering van een eiwit wordt uitgevoerd door een kinase-eiwit. In hoofdstuk 5 
karakteriseren wij de kinase die verantwoordelijk is voor de fosforylering van apoptin. In de 





beide niet voldoen aan de karakteristieken die door ons zijn bepaald, zoals de lokalisatie van 
de kinase in zowel het cytoplasma als de kern.  
 Door transformerende stappen na te bootsen in normale cellen kunnen we 
achterhalen welke veranderde processen leiden tot activering van apoptin in tumorcellen. In 
hoofdstuk 3 leidt ontregeling van de fosfatase ‘protein phosphatase 2A (PP2A)’ in normale 
cellen tot activering van apoptin. Fosfatases zijn eiwitten die fosfaatgroepen verwijderen, de 
tegenhanger van de kinase. Wanneer een fosfatase niet langer correct werkt, blijven er 
bijvoorbeeld eiwitten actief die dat niet zouden moeten zijn.  
 Eén van de meest strikt gereguleerde processen in de cel en daardoor zeer gevoelig 
voor veranderingen die kunnen leiden tot transformatie, is de celdeling. Voordat één cel twee 
cellen kan worden moet al het DNA zorgvuldig worden gekopieerd. Vervolgens moeten 
deze kopieën correct worden verdeeld over de twee dochtercellen. Wanneer hier iets in 
misgaat, leidt dit tot genetische instabiliteit, één van de grootste drijfveren van transformatie. 
PP2A is betrokken bij de controle tijdens de celdeling (mitose). In kankercellen bevinden 
zich vaak mutaties in PP2A die kunnen leiden tot fouten in de mitose en een verdere stap in 
het transformatie proces. Hoofdstuk 6 laat zien dat apoptin in kankercellen de verdeling van 
het DNA tijdens de celdeling grof verstoort, en juist in deze fase van de celcyclus celdood 
(apoptose) induceert via mitotische catastrofe. Waarschijnlijk herkent apoptin het gebrek aan 
controle tijdens de mitose en grijpt dan in. 
 In hoofdstuk 7 vullen we de definities van de ‘hallmarks of cancer’ aan met de 
kennis die wordt verkregen uit het onderzoek naar de werking van apoptin en de rest van de 
PKTCs. Dankzij PKTCs krijgen we meer inzicht in kankerselectieve processen die 
gemanipuleerd kunnen worden om selectief celdood te induceren. Deze kennis zal een 
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